TopPodcast.com
Menu
  • Home
  • Top Charts
  • Top Networks
  • Top Apps
  • Top Independents
  • Top Podfluencers
  • Top Picks
    • Top Business Podcasts
    • Top True Crime Podcasts
    • Top Finance Podcasts
    • Top Comedy Podcasts
    • Top Music Podcasts
    • Top Womens Podcasts
    • Top Kids Podcasts
    • Top Sports Podcasts
    • Top News Podcasts
    • Top Tech Podcasts
    • Top Crypto Podcasts
    • Top Entrepreneurial Podcasts
    • Top Fantasy Sports Podcasts
    • Top Political Podcasts
    • Top Science Podcasts
    • Top Self Help Podcasts
    • Top Sports Betting Podcasts
    • Top Stocks Podcasts
  • Podcast News
  • About Us
  • Podcast Advertising
  • Contact
Not in our directory?
Add Show Here
Podcast Equipment
Center

toppodcastlogoOur TOPPODCAST Picks

  • Comedy
  • Crypto
  • Sports
  • News
  • Politics
  • True Crime
  • Business
  • Finance

Follow Us

toppodcastlogoStay Connected

    View Top 200 Chart
    Back to Rankings Page
    Health & Fitness

    VJOncology Podcast

    The Video Journal of Oncology (VJOncology) podcast covers the latest solid oncology news from international experts, including breast, lung, skin, genitourinary, head and neck, gynecological and more. Made for healthcare professionals and researchers, we are a global, independent, open-access platform. Listen to the latest news, including cutting-edge trial updates, controversies and opinion. If you enjoy the podcast, please leave us a rating and review! For more news visit www.vjoncology.com

    Advertise
    • Apple Podcasts
    • Google Play
    • Spotify
    Latest Episodes:
    Novel therapeutics in PD-1 refractory melanoma Nov 15, 2024

    This week’s podcast from VJOncology explores key advancements in the treatment of PD-1 refractory melanoma. Hear from leading experts, Alison Betoff Warner (Stanford University, Stanford, CA), Andrew Furness (Royal Marsden Hospital, London, UK), Anna Di Giacomo (University Hospital of Siena, Siena, Italy), María Vieito (Vall d’Hebron Institute of Oncology, Barcelona, Spain), and Yana Najjar (UPMC Hillman Cancer Center, Pittsburgh, PA), as they share insights into cutting-edge therapies and trials.

    Highlights include the FDA approval of TIL therapy in metastatic melanoma, early findings on off-the-shelf T-cell therapy, and results from the NIBIT-ML1 trial (NCT04250246) investigating a triple combination of ipilimumab, nivolumab, and ASTX727. Discover updates from the FIRELIGHT-1 study (NCT04985604) on tovorafenib and its efficacy across solid tumors, and learn about challenges in treating acryl and mucosal melanoma from the IGNYTE trial (NCT03767348) of RP1 and a Phase II trial (NCT04493203) of nivolumab with axitinib.

    The post Novel therapeutics in PD-1 refractory melanoma appeared first on VJOncology.

    Climate Change and Other Environmental Factors on Lung Cancer Risk at WCLC 2024 Nov 08, 2024

    In this week’s podcast, we explore the critical links between environmental factors and lung cancer risk, focusing on the impacts of climate change, pollution, and exposure in conflict zones. Join us as we hear from experts Felipe Roitberg, MD, Brazilian Hospital Services Company (EBSERH), Brasília, Brazil, and Leticia Nogueira, MD, American Cancer Society, Palm Harbor, FL.

    They share their insights from the IASLC 2024 World Conference on Lung Cancer (WCLC), highlighting the challenges and innovative solutions emerging from resource-scarce communities worldwide. Discover how climate change affects every stage of cancer care, from prevention to treatment, and the importance of addressing disparities in healthcare access.

    The post Climate Change and Other Environmental Factors on Lung Cancer Risk at WCLC 2024 appeared first on VJOncology.

    GI updates from ESMO 2024 Nov 04, 2024

    This week’s podcast from VJOncology brings you key updates in gastrointestinal cancer from the European Society of Medical Oncology (ESMO) 2024 annual meeting, which took place in Barcelona, Spain.

    Hear from experts, Jessie Elliot (Trinity St. James’s Cancer Institute), Myriam Chalabi (Netherlands Cancer Institute), and Changhoon Yoo (Asan Medical Center) as they discuss the latest in biliary tract and colon cancers, as well as gastric and gastroesophageal junction adenocarcinoma. Highlights include findings from the TOPGEAR trial, extended follow-up results from the NICHE-2 and the NICHE-3 trials, as well as findings from the NIFTY and NALIRICC studies.

    The post GI updates from ESMO 2024 appeared first on VJOncology.

    Updates in the management of refractory colorectal cancer Oct 25, 2024

    In this week’s podcast, we bring you the latest developments in the field of refractory colorectal cancer. We are joined by Rocio Garcia-Carbonero, MD, PhD, University Hospital 12 De Octubre, Madrid, Spain; Kathrin Heinrich, MD, Ludwig-Maximilians-Universität München, Munich, Germany; Chiara Cremolini, MD, PhD, University of Pisa, Pisa, Italy; and Cristina Smolenski, MD, Gustave Roussy, Villejuif, France.

    We’ll hear about the current treatment landscape for refractory metastatic colorectal cancer, especially in the third-line settings, updates from the SOREGATT trial, which assessed regorafenib with chemotherapy in pretreated colorectal cancer, and the emerging role of fruquintinib, a selective VEGFR inhibitor, in patients who progress on regorafenib.

    The post Updates in the management of refractory colorectal cancer appeared first on VJOncology.

    ESSO 43 highlights Oct 11, 2024

    In this podcast, we bring you exclusive insights from the 43rd Congress of the European Society of Surgical Oncology (ESSO 43), held in Antwerp, Belgium. We will be joined by Isabel Rubio, MD, PhD (Vall d’Hebron University Hospital, Barcelona, Spain), who discusses the dual focus of modern cancer surgery and the transformative impact of robotic surgery; Sylvie Bonvalot, MD, PhD, HDR (Institut Curie, Paris, France), recipient of the ESSO Lifetime Achievement Award 2024, who reflects on her extensive experience with desmoid tumors and sarcoma surgery; and Mitsuru Sasako, MD, PhD (Yodogawa Christian Hospital, Osaka, Japan), recipient of the ESSO Gold Medal 2024, who shares remarkable cases in gastric cancer surgery.

    We will hear about the latest advancements in surgical oncology, innovative techniques that enhance patient quality of life, and the significance of collaboration in the field. Additionally, we will discuss the evolution of treatment strategies for desmoid tumors and sarcomas, including active surveillance and limb salvage surgery, and the importance of personalized treatment approaches.

    For more exclusive content on ESSO 43, visit VJOncology.com.

    The post ESSO 43 highlights appeared first on VJOncology.

    Highlights from ESMO 2024 Sep 20, 2024

    In this week’s podcast, we bring you updates from the ESMO 2024 Congress in Barcelona, Spain, featuring expert discussions on cutting-edge oncology research. We are joined by Peter Schmid, FRCP, MD, PhD, Barts Cancer Institute, London, UK; Minke Lukas, MD, Netherlands Cancer Institute, Amsterdam, Netherlands; Guru Sonpavde, MD, AdventHealth Cancer Institute, Orlando, FL; Sanjay Popat, MBBS, FRCP, PhD, The Royal Marsden Hospital, London, UK; Domenica Lorusso, MD, PhD, Fondazione IRCCS National Cancer Institute of Milan, Italy; and Dominik Modest, MD, Charité – Universitätsmedizin Berlin, Germany.

    We’ll hear about final overall survival results from the Phase III KEYNOTE-522 trial (NCT03036488) of pembrolizumab in triple-negative breast cancer, updates from the Phase III NADINA trial (NCT04949113) of ipilimumab and nivolumab in melanoma, and findings from the Phase III AMBASSADOR trial (NCT03244384) of adjuvant pembrolizumab in urothelial carcinoma, as well as the Phase III NIAGARA trial (NCT03732677) of neoadjuvant immunotherapy in muscle-invasive bladder cancer. Other highlights include data from the Phase III MARIPOSA-2 trial (NCT04487080) of amivantamab in EGFR-mutant lung cancer, the Phase III KEYNOTE-A18 (NCT04221945) study in cervical cancer, and the Phase III POD1UM-303 trial (NCT04472429) of retifanlimab in squamous cell anal carcinoma.

    For more exclusive content on ESMO 2024, visit VJOncology.com.

    The post Highlights from ESMO 2024 appeared first on VJOncology.

    Latest updates in managing brain metastases Sep 11, 2024

    In this podcast, we bring you the latest insights into managing brain metastases, with expert commentary from Minesh Mehta, MD, Miami Cancer Institute, Miami, FL; Sunandana Chandra, MD, MS, Northwestern University, Chicago, IL; Gaia Griguolo, MD, University of Padova, Padova, Italy; Orit Kaidar-Person, MD, Sheba Medical Center, Ramat Gan, Israel; and Janice Wing-Hang Tsang, MBBS, MRCP, FRCP, University of Hong Kong, Hong Kong, China,.

    We will cover key findings from the Phase III METIS trial (NCT02831959), which explored Tumor Treating Fields (TTFields) therapy in patients with non-small cell lung cancer and brain metastases. Other topics include the complexities of managing symptomatic brain metastases in melanoma, new advances in breast cancer treatment with anti-HER2 agents, and the role of radiotherapy in preserving cognitive function. Finally, we’ll discuss data from the DESTINY-Breast01, -02, and -03 trials (NCT03248492, NCT03523585, NCT03529110) on the CNS efficacy of trastuzumab deruxtecan (T-DXd).

    Subscribe to our podcasts on Apple Podcasts, Podbean, and Spotify and join the conversation via X (formerly Twitter) @VJOncology. For more updates in the field, visit VJOncology.com.

    The post Latest updates in managing brain metastases appeared first on VJOncology.

    Updates in immunotherapy for GU cancer Aug 23, 2024

    In this podcast, we highlight some of the latest updates in the use of immunotherapy to treat genitourinary cancer. This week we will be joined by Camillo Porta, MD, University of Bari Aldo Moro, Bari, Italy, Joaquim Bellmunt, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, Arlene Siefker-Radtke, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Maria Bourlon, MD, MS, El Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.

    We will cover findings from key trials, including CHECKMATE 901 on nivolumab with gemcitabine and cisplatin for metastatic urothelial carcinoma; JAVELIN Renal 101 comparing avelumab plus axitinib with sunitinib for advanced renal cell carcinoma; a JAVELIN Bladder 100 post hoc analysis on avelumab for first-line maintenance in advanced urothelial carcinoma; TROPiCS-04 on sacituzumab govitecan in advanced urothelial carcinoma; and CheckMate 67T comparing subcutaneous and intravenous nivolumab for advanced renal cell carcinoma

    For other GU cancer news, be sure to visit our dedicated GU Cancer Channel.

    Subscribe to our podcasts on Apple Podcasts, Podbean, and Spotify and join the conversation via X (formerly Twitter) @VJOncology. For more updates in the field, visit vjoncology.com.

    The post Updates in immunotherapy for GU cancer appeared first on VJOncology.

    Advancements in precision medicine for colorectal cancer Aug 09, 2024

    In this week’s podcast, we will be covering recent updates and integrating precision medicine for the treatment of colorectal cancer. We’ll be covering a wide range of topics including biomarker-driven treatments, challenges in using minimal residual disease in the clinic and more.

    Listen to expert insights from Scott Kopetz, The University of Texas MD Anderson Cancer Center, Houston, TX, Giulia Martini, University of Campania Luigi Vanvitelli, Naples, Italy, Paolo Manca, Memorial Sloan Kettering Cancer Center, New York, NY, and Eric Christensen, John Hopkins Medicine, Baltimore, MD, as they discuss hurdles and opportunities in precision medicine for colorectal cancer.

    The post Advancements in precision medicine for colorectal cancer appeared first on VJOncology.

    iwCAR-T sessions: clinical advances in GI Cancers Aug 07, 2024

    In this podcast, we join leading experts Randy Hecht from UCLA, Diane Simeone from University of California San Diego, and Ben Schechter from Dana-Farber Cancer Institute as they delve into groundbreaking advancements in GI cancer therapies, as presented at the latest iwCAR-T workshop in Miami, Florida.

    Explore the latest updates and insights on translational research in pancreatic cancer, including innovative biopsy techniques and the evolving role of immuno-oncology in treating solid tumors. Discover the potential of new cell therapies like TAC T-cells and the promising Claudin 18.2-targeted therapies, highlighting their efficacy and safety profiles. These discussions underscore the need for continued research in precision oncology and the adaptation of hematologic malignancy successes to solid tumors.

    The post iwCAR-T sessions: clinical advances in GI Cancers appeared first on VJOncology.

    iwCAR-T sessions: cell therapies for melanoma and sarcomas Jul 26, 2024

    In this week’s podcast, we join experts Allison Betof Warner from Stanford Medicine, Amod Sarnaik from Moffitt Cancer Center, and Elizabeth Loggers from Fred Hutchinson Cancer Center on transformative innovations in cell therapies for melanoma and sarcomas, as presented at the most recent iwCAR-T workshop in Miami, Florida.

    Discover the latest updates and perspectives on advanced TIL therapies, including their promising progression-free survival results and new protocols for melanoma-induced brain metastases, along with updates on TCR-based therapies for synovial sarcoma. These developments underscore the need for continued research in adjuvant treatment settings and tumor immunology.

    The post iwCAR-T sessions: cell therapies for melanoma and sarcomas appeared first on VJOncology.

    iwCAR-T sessions: Advances in breast and gynecological cancers Jul 19, 2024

    In this week’s episode, we join Jennifer Specht from Fred Hutchinson Cancer Center, Saurabh Garg from Moffitt Cancer Center, and Rizwan Romee from Dana-Farber Cancer Institute on pioneering advancements in CAR-T cell therapies for breast and gynecological cancers, as discussed at the recent 6th annual iwCAR-T workshop in Miami, Florida.

    Tune in to learn about the fascinating evolution of ROR1-targeting CAR-T cells for triple negative breast cancer, NK-cell targeting CAR-T therapeutics in ovarian cancer, and combinatorial therapy using dendritic cells against HER2-positive breast cancer. As their development progresses, several challenges and advantages come to light.

    The post iwCAR-T sessions: Advances in breast and gynecological cancers appeared first on VJOncology.

    iwCAR-T sessions: clinical advances in lung cancer Jul 12, 2024

    Welcome to another episode of VJOncology! In this episode, we dive into cutting-edge CAR-T cell therapies for the management of lung cancers, discussed at the sixth International Workshop on CAR-T in Miami, Florida.

    Join Julian Molina from the Mayo Clinic, Ben Creelan from Moffitt Cancer Center, and Adam Schoenfeld from Memorial Sloan Kettering Cancer Center as they explore innovative CAR-T strategies and their applications in thoracic oncology. They address the challenges of integrating cell therapies in clinical practice, the potential for tumor cell banking, and the implications of tumor microenvironment modulation.

    Discover insights into the latest developments in claudin-targeting CAR-T cells for non-small cell lung cancer and the exciting prospects of DLL3-targeting therapies for neuroendocrine tumors. This episode provides a comprehensive overview of the future landscape of cell therapy in lung cancer treatment.

    Don’t miss this enlightening discussion! Subscribe and leave a review on your favorite podcast app. Follow us on Twitter at VJOncology and visit vjoncology.com for more content from the International Workshop on CAR-T.

    The post iwCAR-T sessions: clinical advances in lung cancer appeared first on VJOncology.

    Highlights in colorectal cancer at ASCO and ESMO GI 2024 Jul 05, 2024

    In this week’s podcast, we will discuss the most recent developments in colorectal cancer from the 2024 ASCO and ESMO Gastrointestinal (GI) Annual Meetings held in Chicago, IL and Munich, Germany respectively. Join us as five renowned experts discuss highly anticipated findings from clinical trials across different colorectal cancer subtypes.

    Heinz-Josef Lenz from the University of Southern California first comments on the expanded efficacy analysis from the Phase III CheckMate 8HW study in MSI-H/dMMR metastatic colorectal cancer and Sara Lonardi from the Veneto Institute of Oncology in Padua, Italy, discusses the health-related quality of life outcomes from the trial. John Strickler from Duke University then provides 32 month follow-up data from the MOUNTAINEER trial of tucatinib and trastuzumab in HER2+ colorectal cancer. Additionally, listen to insightful perspectives from Major Lee, The University of Pennsylvania, and David Tougeron, Poitiers University Hospital, on practice changing trials in colorectal cancer.

    The post Highlights in colorectal cancer at ASCO and ESMO GI 2024 appeared first on VJOncology.

    Skin Cancer Highlights at ASCO 2024 Jun 24, 2024

    Welcome to another episode of VJ Oncology Podcasts! Today, we spotlight key advances in skin cancer research shared at ASCO 2024. Join us as six leading experts reveal groundbreaking findings from recent clinical trials.

    First, Georgina Long from the University of Sydney discusses the NADINA trial, a landmark Phase III study on neoadjuvant immunotherapy for melanoma. Next, Omid Hamid from The Angeles Clinic presents early results from a Phase I trial of IMC-F106C in metastatic cutaneous melanoma. Hear insights from Meredith McKean, Sapna Patel, Joseph J. Sacco, and Rodabe Amaria on innovative therapies and trial results shaping the future of skin cancer treatment. Tune in for these and more exciting updates!

    The post Skin Cancer Highlights at ASCO 2024 appeared first on VJOncology.

    iwCAR-T sessions: Clinical Advances in Head and Neck Cancer and Brain Tumors Jun 07, 2024

    Welcome to another episode of VJ Oncology! In this episode, we delve into pioneering CAR-T strategies for head and neck cancers and brain tumors, as discussed at the recent iwCAR-T workshop in Miami, Florida.

    Join Kedar Khartani from Moffitt Cancer Center and Susanna Baumeister from Dana-Farber Cancer Institute as they explore groundbreaking CAR-T approaches and clinical trials targeting glioblastoma and neuroblastoma. They address the challenges and future prospects of commercializing these therapies, particularly for rare and pediatric cancers.

    Discover the exciting developments in ALK-targeting CAR-T cells for neuroblastoma and new antigen-selected TIL therapies for head and neck cancers. This episode offers valuable insights into the evolving landscape of cell therapy in oncology.

    Don’t miss this informative discussion! Subscribe and leave a review on your favorite podcast app. Follow us on Twitter at VJ Oncology and visit vjoncology.com for more content from the iwCAR-T workshop.

    The post iwCAR-T sessions: Clinical Advances in Head and Neck Cancer and Brain Tumors appeared first on VJOncology.

    ELCC 2024 Highlights May 24, 2024

    This week, we bring you key highlights from European Lung Cancer Congress (ELCC) 2024, which took place in Prague, Czech Republic, including the EVOKE-02, IMscin002, FLAURA2, MARIPOSA-2 and PAPILLON clinical trials. Hear from Federico Cappuzzo, AUSL della Romagna-Ravenna, Ravenna, Italy, Natalia Valdiviezo, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru, Alexander Spira, Next Oncology-Virginia VCS, Joshua Sabari, NYU Langone Health, New York, NY, as they talk on exciting results in lung cancer.

    The post ELCC 2024 Highlights appeared first on VJOncology.

    Key Updates at ESMO Breast 2024 May 17, 2024

    In today’s episode, we bring you key highlights from ESMO Breast 2024, diving into important discussions surrounding the latest research and clinical data regarding breast cancer. We bring insights from top field experts, set to enlighten you on new breakthroughs and developments, including updates from the DESTINY-Breast02 trial as well as first-line CDK4/6 inhibitor clinical data in HR+/HER2-advanced breast cancer.

    The post Key Updates at ESMO Breast 2024 appeared first on VJOncology.

    Bladder Cancer Awareness Month Part II: Management of UC in the UK May 10, 2024

    In this podcast, we continue to commemorate Bladder Cancer Awareness Month in May with a special limited series, where we invite a special guest to discuss and share their expert perspectives within this ever evolving field. This week, Rob Jones, MD, PhD, University of Glasgow, Glasgow, UK, will be talking about first-line treatment paradigms in bladder cancer, survivorship challenges, and the current state of bladder cancer treatment in the UK.

    The post Bladder Cancer Awareness Month Part II: Management of UC in the UK appeared first on VJOncology.

    Bladder Cancer Awareness Month Part I: The past, present, and future of ADCs May 03, 2024

    In this podcast, we commemorate Bladder Cancer Awareness Month in May with a special limited series, where we invite a special guest to discuss and share their expert perspectives within this ever evolving field. This week, Jonathan Rosenberg, MD, Memorial Sloan Kettering Cancer Center, New York, NY, will be talking about antibody-drug conjugates, which have made a big impact in the treatment landscape of bladder cancer and other solid tumors. He will provide his thoughts on the approval of enfortumab vedotin, managing toxicities, and the future of ADCs.

    The post Bladder Cancer Awareness Month Part I: The past, present, and future of ADCs appeared first on VJOncology.

    BTOG 2024 Highlights Apr 26, 2024

    Tune in to an insightful podcast hosted by VJOncology, featuring experts from BTOG 2024 discussing advancements in lung cancer research.

    Prof. Charles Swanton (Francis Crick Institute, London, UK) delves into the link between air pollution and cancer development. Dr Thomas Newsom-Davies (Chelsea and Westminster Hospital NHS Foundation Trust, London, UK) highlights progress in TNM staging and immunotherapy. Dr Mariana Brandao (Institute Jules Bordet, Brussels, Belgium) addresses operability in non-small cell lung cancer, stressing the need for thorough assessments. Dr Robert Rintau (University of Cambridge & Royal Papworth Hospital NHS Foundation Trust, Cambridge, UK) discusses implications of improved survival rates and evolving treatments. Dr Crispin Hiley (UCL, London, UK) reflects on the HIT-Meso trial, while Prof. Sanjay Popat (The Royal Marsden NHS Foundation Trust, London, UK) underscores the success of BTOG 2024 in representing multidisciplinary teams. Explore the dynamic landscape of lung cancer treatment and research. Listen now for valuable insights.

    The post BTOG 2024 Highlights appeared first on VJOncology.

    Highlights from AACR 2024: KRYSTAL-1, FLAURA2, and EDGE Apr 12, 2024

    This week, we cover key updates from the American Association for Cancer Research (AACR) 2024 Annual Meeting, held in San Diego, CA. Hear from Scott Koptez, The University of Texas MD Anderson Cancer Center, Houston, TX, Rebecca Porter, Dana-Farber Cancer Institute, Boston, MA, Pasi Janne, Dana-Farber Cancer Institute, Boston, MA, and Elizabeth Swisher, Fred Hutchinson Cancer Center, Seattle, CA, as they discuss takeaways from the meeting.

    The post Highlights from AACR 2024: KRYSTAL-1, FLAURA2, and EDGE appeared first on VJOncology.

    Updates in immunotherapy for head and neck cancer Mar 28, 2024

    In this podcast, we highlight some of the latest updates in the use of immunotherapy to treat head and neck cancer. This week we will be joined by Nicolas Mach, MD, Hôpitaux Universitaires de Genève, Geneva, Switzerland; Emrullah Yilmaz, MD, PhD, Cleveland Clinic, Cleveland, OH; Emrullah Yilmaz, MD, PhD, Cleveland Clinic, Cleveland, OH; Ari Rosenberg, MD, University of Chicago, Chicago, IL and Nabil Saba, MD, FACP, Winship Cancer Institute of Emory University, Atlanta, GA.

    We will hear about the results of the SAKK 11/16 trial (NCT02999646) of the MVX-ONCO-1 vaccine, a Phase I dose expansion trial (NCT04429542) of BCA101, a bifunctional EGFR/TGFβ inhibitor, with pembrolizumab, and increasing T-cell responses in HPV-positive head and neck cancer with TheraT vectors, as well as other novel immunotherapy approaches.

    For other head and neck cancer news, head over to our Head and Neck Cancer Channel. Subscribe to our podcasts on Apple Podcasts, Podbean, and Spotify and join the conversation via X (formerly Twitter) @VJOncology. For more updates in the field, visit vjoncology.com.

    The post Updates in immunotherapy for head and neck cancer appeared first on VJOncology.

    Updates in immunotherapy for skin cancer Mar 22, 2024

    In this podcast, we highlight some of the latest updates in the use of immunotherapy to treat skin cancer. This week, we will be joined by Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA; Paolo Ascierto, MD, Istituto Tumori Fondazione Pascale, Naples, Italy; Georgina Long, PhD, MBBS, FRACP, FAHMS, The University of Sydney, North Sydney, Australia; and Karijn Suijkerbuijk, MD, PhD, UMC Utrecht, Utrecht, The Netherlands.

    We will hear on the impact of T-Cell therapies, such as lifileucel, in patients with melanoma; results of the 7-year CheckMate 238 trial (NCT02388906) of nivolumab; effective sequencing of treatments in the SECOMBIT trial (NCT02631447); and challenges in managing immunotherapy related adverse events.

    If you would like to learn more about the recent approval of lifileucel by the FDA, you can find our feature article here. For other skin cancer news, be sure to visit our dedicated Skin Cancer Channel.

    Subscribe to our podcasts on Apple Podcasts, Podbean, and Spotify and join the conversation via X (formerly Twitter) @VJOncology. For more updates in the field, visit vjoncology.com.

    The post Updates in immunotherapy for skin cancer appeared first on VJOncology.

    Highlights in colorectal cancer at ASCO GI 2024 Mar 08, 2024

    In this week’s podcast by VJ Oncology, six leading experts share their insights on cutting-edge developments in colorectal cancer screening and treatment, drawn from highlights of the 2024 ASCO Gastrointestinal (GI) Cancers Symposium held in San Francisco, CA. One key focus was the rapid evolution of non-invasive blood-based tests for colorectal cancer screening, as discussed by Aasma Shauka from New York University. Further, Theodore R. Levin from Kaiser Permanente shared the effectiveness of stool-based testing in achieving high adherence rates for colorectal cancer screening. Meanwhile, Sebastian Stintzing from Charité – Universitätsmedizin Berlin analyzed the Phase II FRASCO2 trial, demonstrating the benefit of fruquintinib for heavily pre-treated patients with refractory metastatic colorectal cancer in a Q-TWIST analysis. Edward Esplin from Invitae speaks on the potential of personalized monitoring tests in early-stage colorectal cancer treatment and Van K. Morris from the University of Texas analyzing a prospective phase 2 clinical trial for previously treated metastatic colorectal cancer. Finally, Anwar Saeed’s discusses the rationale behind STELLAR-303 trial aiming to address unmet needs of patients with specific types of metastatic colorectal cancer.

    The post Highlights in colorectal cancer at ASCO GI 2024 appeared first on VJOncology.

    Targeted therapies for lung cancer at TTLC 2024 Mar 01, 2024

    This week, we cover interesting research from TTLC 2024, focusing on innovative treatments for lung cancer. Starting off, Bruna Pellini from Moffitt Cancer Center, FL, talks about the utility of circulating tumor DNA as a biomarker of progression in lung cancer, her latest findings from notable Phase III trials and ongoing studies looking into increasing treatment based on this biomarker.

    Next, Monica Chen from Memorial Sloan Kettering Cancer Center, NY, discusses the role of osimertinib with chemotherapy as initial treatment for patients with metastatic EGFR mutant lung cancers with concurrent TP53 and RB1 alterations from a clinical trial perspective.

    Our final speaker, Timothy Burns from University of Pittsburgh, PA, shares detailed insights into non-TKI treatment options for EGFR mutant lung cancer. He discusses the exciting prospects of upcoming studies, potential FDA approvals and the integrated role of immuno-modulatory agents in EGFR mutant patients.

    Our podcast aims to deliver the latest and most intriguing updates in the field directly to you. Follow us on Twitter at @vjoncology and visit our website for the newest trends.

    The post Targeted therapies for lung cancer at TTLC 2024 appeared first on VJOncology.

    Updates in invasive lobular carcinoma (ILC) Feb 23, 2024

    Invasive lobular carcinoma (ILC) poses unique challenges in breast cancer management. Its subtle presentation and distinct biological behavior demand a nuanced approach from healthcare professionals. In this podcast, we delve into the epidemiology, pathology, diagnostic methods, treatment modalities, and emerging research surrounding ILC. By comprehensively understanding this subtype, healthcare professionals can optimize patient care and ultimately improve patient outcomes. In this enlightening podcast from VJ Oncology, join our distinguished guests, Jason Aboudi Mouabbi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Fresia Pareja, MD, Memorial Sloan Kettering Cancer Center, New York, NY, as they delve into the complexities of ILC.

    The post Updates in invasive lobular carcinoma (ILC) appeared first on VJOncology.

    Esophageal and gastric cancer highlights from ASCO GI 2024 Feb 16, 2024

    In this podcast, we will discuss key insights from the 2024 ASCO Gastrointestinal (GI) Cancers Symposium held in San Francisco, CA. Topics include updates in the KEYNOTE-811, MATTERHORN, and CheckMate 649 trials, as well as the use of circulating free DNA analysis in esophagogastric cancer and the evolving landscape of treatment of HER2-positve metastatic gastric cancer. Additionally, hear on a pilot PET study using the positron-emitting agent 18F-BMS-986229 for PD-L1 imaging in advanced esophagogastric cancer and a retrospective investigation into the concordance between three PD-L1 scoring methods and their association with clinical outcomes in RATIONALE-302.

    Tune in to hear perspectives from experts such as Yelena Y. Janjigian (Memorial Sloan Kettering Cancer Center, New York, NY), Samuel Louis Cytryn (Memorial Sloan Kettering Cancer Center, New York, NY), Kohei Shitara (National Cancer Center Hospital East, Kashiwa, Japan), Ken Kato (National Cancer Center Hospital, Tokyo, Japan) and Nataliya V. Uboha (University of Wisconsin Carbone Cancer Center, Madison, WI).

    The post Esophageal and gastric cancer highlights from ASCO GI 2024 appeared first on VJOncology.

    Key updates at ASCO GU 2024 Feb 09, 2024

    In this podcast, we will discuss key insights from the 2024 ASCO Genitourinary (GU) Cancers Symposium held in San Francisco, CA. Topics include updates in the AMBASSADOR, CONTACT-2, and CLEAR trials, as well as why BCG-unresponsive patients with non-muscle invasive bladder cancer refuse cystectomy and the emerging role transperineal prostate biopsies. Tune in to hear perspectives from experts such as Andrea Apolo (National Institutes of Health, Bethesda, MD), Kim Chi (BC Cancer Vancouver Centre, Vancouver, Canada), Viktor Grünwald (University Hospital Essen, Essen, Germany), Joseph Jacob (Upstate Medical University, Syracuse, NY), and Jim Hu (Weill Cornell Medicine, New York, NY).

    The post Key updates at ASCO GU 2024 appeared first on VJOncology.

    Highlights in bladder and prostate cancer at PROCSA/BLADDR 2023 Feb 02, 2024

    In this podcast, we’ll be covering highlights from the PROCSA/BLADDR 2023 Meeting, which took place in Valencia, Spain, such as the evolution of targeted therapies and novel biomarker driven studies in prostate cancer, as well as trimodal therapy for non-muscle invasive bladder cancer. Hear from Rob Jones (The University of Glasgow, Glasgow, UK), Bertrand Tombal (Université catholique de Louvain, Ottignies-Louvain-la-Neuve, Belgium), Daniele Raggi (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy), Bram De Laere (Ghent University, Ghent, Belgium), Paul Sargos (Institut Bergonié, Bordeaux, France), Felix Guerrero-Ramos (Hospital Universitario 12 de Octubre, Madrid, Spain), Eva Compérat (Medical University of Vienna, Vienna, Austria).

    The post Highlights in bladder and prostate cancer at PROCSA/BLADDR 2023 appeared first on VJOncology.

    Key updates at ESMO Asia 2023 Jan 26, 2024

    The recent European Society for Medical Oncology (ESMO) Asia 2023 Congress in Singapore, brought together key oncology experts to delve into the latest oncology advancements. In this podcast episode, we are honored to host discussions with distinguished guests: Enrique Grande (MD Anderson Cancer Centre Madrid, Madrid, Spain), Molly Li (Queen Elizabeth Hospital, Hong Kong), Karijn Suijkerbuijk (UMC Utrecht, Utrecht, The Netherlands), and Hidehito Horinouchi (National Cancer Center Hospital, Tokyo, Japan).

    The conversation will provide insights into noteworthy perspectives on cellular therapy development in Asia, the use of immunotherapies for advanced acral and mucosal melanoma, novel ADCs in EGFR-mutant lung cancer and a potential new standard of care in urothelial cancer.

    The post Key updates at ESMO Asia 2023 appeared first on VJOncology.

    Breast Cancer Sessions: Highlights from SABCS 2023 with Sara Tolaney, Sarah Sammons & Paolo Tarantino Jan 12, 2024

    The San Antonio Breast Cancer Symposium (SABCS) 2023 took place on the 5-9th of December 2023 in San Antonio, TX. Leading experts in breast cancer came together to hear the latest clinical trial data and discuss how to improve care for patients with breast cancer.

    In this podcast, we hear from Sara Tolaney, MD, MPH, Sarah Sammons, MD, and Paolo Tarantino, MD, of Dana-Farber Cancer Institute, Boston, MA, as they discuss the hot topics from SABCS 2023 in an exclusive roundtable discussion. Topics covered include updates on the management of HR+/HER2- breast cancer such as the role of CDK4/6 inhibitors as evaluated in MONARCH 3 (NCT02246621) and PARSIFAL (NCT02491983), the potential of PIK3CA described in the INAVO120 trial (NCT04191499), the use of ribociclib and endocrine therapy as adjuvant treatment in HR+/HER2- early breast cancer, and finally neoadjuvant immunotherapy in HR-positive early breast cancer.

    The post Breast Cancer Sessions: Highlights from SABCS 2023 with Sara Tolaney, Sarah Sammons & Paolo Tarantino appeared first on VJOncology.

    Updates in GI cancer at ESMO 2023 Jan 05, 2024

    The European Society for Medical Oncology (ESMO) Congress 2023 brought together leading experts to explore and deliberate on the most recent advancements and breakthroughs in the field of oncology. In this podcast, joining us will be John H. Strickler (Duke Cancer Institute, Durham, NC), Stephen L. Chan (The Chinese University of Hong Kong, Hong Kong, China), Benedikt Westphalen (Ludwig-Maximilians-University (LMU) Hospital, Munich, Germany), Filippo Pietrantonio (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy), Yoshiaki Nakamura (National Cancer Center Hospital East, Kashiwa, Japan) and Lorenza Rimassa (Humanitas University, Milan, Italy).

    Discussions cover updates from various trials, emphasizing the effectiveness of tucatinib plus trastuzumab in HER2-positive RAS-WT metastatic colorectal cancer (mCRC) in the MOUNTAINEER (NCT03043313) trial and sotorasib with panitumumab in KRAS G12C mCRC in the CodeBreak 300 trial. Trials in hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) trials are highlighted and data on ctDNA as a prognostic biomarker in resected CRC is discussed, as well as prognostic factors contributing to long-term survivorship in patients with hepatobiliary cancers and advances in targeting KRAS in GI malignancies.

    The post Updates in GI cancer at ESMO 2023 appeared first on VJOncology.

    2023 updates in metastatic colorectal cancer genomic biomarkers Dec 22, 2023

    Huge advancements in personalized medicine and the availability of genetic testing have led us to consider the use of genomic alterations as biomarkers in cancer treatment. In this podcast, we will revisit the most recent developments in the efficacy and clinical application of genomic biomarkers in metastatic colorectal cancer (mCRC) presented during 2023.

    We will hear from Filippo Pietrantonio, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, regarding the CodeBreak 300 trial (NCT05198934); John H. Strickler, MD, Duke Cancer Institute, Durham, NC, on MOUNTAINEER (NCT03043313); Ardaman Shergill, MD, University of Chicago, Chicago, IL, on PARADIGM (NCT02394795), STRATEGIC-1 (NCT01910610) and CAIRO5 (NCT02162563), and Benny Johnson, DO, The University of Texas MD Anderson Cancer Center, Houston, TX, who rounds off the discussion by considering the use of circulating tumor DNA (ctDNA) to assess minimal residual disease (MRD) status.

    Be sure to visit our dedicated page on genomic biomarkers in metastatic colorectal cancer here to learn more about current and future biomarker testing standards, as well as potential treatment directions in the future.

    The post 2023 updates in metastatic colorectal cancer genomic biomarkers appeared first on VJOncology.

    Highlights in cancer nursing at UKONS 2023 Dec 01, 2023

    The 2023 UK Oncology Nursing Society (UKONS) meeting, which took place in Newport, Wales, gathered leading oncology experts to discuss the latest developments in cancer nursing. In this podcast, we will be joined by Verna Lavender, PhD (Guy’s and St Thomas’​ NHS Foundation Trust, London, UK), Gina Madera (The Christie NHS Foundation Trust, Manchester, UK), and Sarah Adomah (The Royal Marsden NHS Foundation Trust, London, UK).

    We will hear on updates on important initiatives and programs such as the Creation of Acute oncology Standardized Competence Assessment Documents and their Evaluation (CASCADE) project, which aims to enhance cancer education in the UK.

    The post Highlights in cancer nursing at UKONS 2023 appeared first on VJOncology.

    Highlights in gynecologic cancer from ESMO 2023 Nov 24, 2023

    The European Society for Medical Oncology (ESMO) Congress 2023 gathered prominent experts to discuss the latest research and breakthroughs in oncology. In this podcast, joining us will be Mary McCormack (UCL Hospitals NHS Foundation Trust, London, UK), Benoit You (Lyon University Hospital, Lyon, France), Domenica Lorusso (Fondazione IRCCS National Cancer Institute of Milan, Italy), Mansoor Raza Mizra (Copenhagen University Hospital, Denmark) and Shannon N. Westin (MD Anderson Cancer Center, Houston, TX).

    Updates from multiple trials are discussed, highlighting the efficacy of induction chemotherapy plus chemoradiation in the INTERLACE trial, the combination of pembrolizumab with chemoradiation in the KEYNOTE-A18 trial (NCT04221945), and the potential of tisotumab vedotin in the innovaTV 301 trial (NCT04697628)—all focusing on advanced cervical cancer. Additionally, discussions cover the RUBY (NCT03981796) and DUO-E (NCT04269200) trials exploring the use of various immunotherapy agents combined with chemotherapy for the treatment of advanced endometrial cancer.

    The post Highlights in gynecologic cancer from ESMO 2023 appeared first on VJOncology.

    Highlights in breast cancer from ESMO 2023 Nov 17, 2023

    The European Society for Medical Oncology (ESMO) Congress 2023, which took place in Madrid, Spain, gathered internationally acclaimed experts to share and deliberate on the most recent breakthroughs in oncology. In this podcast, we listen to prominent healthcare professionals offering a summary of key moments from this year’s conference.

    Today we are joined by Peter Schmid (Barts Cancer Institute, London, UK), Erika Hamilton (Sarah Cannon Research Institute, Nashville, TN), Kevin Kalinsky (Emory University Hospital, Atlanta, GA), and Sherene Loi (Peter MacCallum Cancer Centre, Victoria, Australia), who share key updates in breast cancer at ESMO 2023. Topics discussed include findings from the BEGONIA (NCT03742102), KEYNOTE-522 (NCT03036488), CheckMate7FL trials (NCT04109066), novel estrogen receptor degraders vepdegestrant, as well the current state of CDK4/6 inhibitors in metastatic HER2-negative breast cancer.

    The post Highlights in breast cancer from ESMO 2023 appeared first on VJOncology.

    Highlights in lung cancer from ESMO 2023 Nov 10, 2023

    The European Society for Medical Oncology Annual Meeting (ESMO) 2023 brought together thousands of experts in oncology to hear new data and discuss how to improve the diagnosis and treatment of patients with cancer. In this podcast, we will be joined by Nicolas Girard (Institut Curie, Paris, France), Crispin Hiley (UCL Cancer Institute, London), Byoung Chul Cho (Yonsei University, Seoul, Korea), Benjamin Besse (Gustave Roussy, Villejuif, France), and James R. Black (UCL, London, UK).

    We will hear key updates on crucial clinical trials including the Phase III PAPILLON trial of amivantamab plus chemotherapy in EGFR Exon 20 non-small cell lung cancer (NSCLC), the Phase II DARWIN II trial deciphering anti-tumor response and resistance to immunotherapy with intratumor heterogeneity in NSCLC and the Phase III MARIPOSA trial of amivantamab combined with lazertinib for EGFR-muted NSCLC. We will also delve into the safety, efficacy and ongoing evaluation of AZD7789, a novel PD-1 and TIM-3 targeting bispecific antibody, as well as data on an ultra-sensitive and specific ctDNA assay for early-stage lung cancer.

    The post Highlights in lung cancer from ESMO 2023 appeared first on VJOncology.

    Highlights in GU cancer at ESMO 2023 Nov 03, 2023

    The European Society for Medical Oncology (ESMO) Congress 2023, which took place in Madrid, Spain, gathered internationally acclaimed experts to share and deliberate on the most recent breakthroughs in oncology. In this podcast, we listen to prominent healthcare professionals offering a summary of key moments from this year’s conference. We will be joined by Joaquim Bellmunt (Harvard Medical School, Boston, MA), Laurence Albiges (Gustave Roussy Institute, Villejuif, France), Arlene Siefker-Radtke (The MD Anderson Cancer Center, Houston, TX), and Bradley McGregor (Dana Farber Cancer Institute, Boston).

    We will hear on updates on pivotal trials including the Phase III EV-302 trial of enfortumab vedotin and pembrolizumab in untreated advanced/metastatic urothelial cancer, as well as the Phase III LITESPARK-005 trial of belzutifan versus everolimus in patients with pretreated advanced clear cell renal cell carcinoma (ccRCC). Additional trials under discussion include the THOR study of erdafitinib versus pembrolizumab in pre-treated patients with urothelial cancer and the DAD trial of sacitizumab govetican and enfortumab vedotin as a second-line therapy in patients with metastatic urothelial carcinoma.

    The post Highlights in GU cancer at ESMO 2023 appeared first on VJOncology.

    EGFR exon 20 insertions and how to manage patients in the UK Oct 13, 2023

    EGFR exon 20 insertion mutations represent 5% to 10% of EGFR mutations in patients with non-small cell lung cancer (NSCLC). Despite this form of lung cancer being hard to detect in standard genetic testing, mobocertinib and amivantamab have shown promising results in clinical trials.

    In this week’s podcast, join Sanjay Popat, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, UK, Alastair Greystoke, MBChB, MSc, PhD, MRCP, University of Newcastle & Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, Anna Minchom, MD, MRCP, MBBCh, The Royal Marsden NHS Foundation Trust, London, UK, and Riyaz Shah, MBBS, FRCP, PhD, Kent Oncology Centre, Maidstone, UK, as will discuss the identification of EGFR exon 20 insertions and how to manage patients in the UK, based on the recent decisions made by NICE on the use of amivantamab and mobocertinib.

    The post EGFR exon 20 insertions and how to manage patients in the UK appeared first on VJOncology.

    Updates in immunotherapy for brain tumors Sep 15, 2023

    Even with aggressive surgical procedures, radiation therapy, and systemic chemotherapy, the outlook for individuals diagnosed with malignant brain tumors remains dismal, and conventional treatments come with notable risks of causing long-term cognitive impairments. There is a pressing and evident demand for the advancement of more efficient therapies that can complement standard approaches for invasive brain cancers while minimizing their harmful side effects. Cancer immunotherapy emerges as a hopeful treatment strategy capable of providing precise tumor-targeted cytotoxicity, offering the potential to eradicate brain tumor cells while preserving the delicate functions of the brain.

    In this podcast we hear from Olivia Rongze Lu, PhD, University of California San Francisco, San Francisco, CA, Stephen Joseph Bagley, MD, MSCE, Hospital of the University of Pennsylvania, PA, Anthony Chalmers, MD, University of Glasgow, Glasgow, UK, and Philipp Karschnia, MD, Ludwig-Maximilians-University, Munich, Germany, as they discuss updates in immunotherapy for brain tumors.

    The post Updates in immunotherapy for brain tumors appeared first on VJOncology.

    Developments in Radiotherapy for GI Cancer Sep 08, 2023

    For various gastrointestinal (GI) malignancies such as gastric and pancreatic cancer, chemotherapy and surgery remain the standard of care. Numerous trials have been conducted to assess the effectiveness of radiotherapy and chemoradiotherapy in the management of GI cancer.

    In this podcast, we hear from Lucjan Wyrwicz, MD, PhD, Maria Sklodowska-Curie National Cancer Research Institute, Warsaw, Poland, Sushma Agrawal, MD, SGPGI, Lucknow, India, Joseph Herman, MD, MSc, MHCM, Northwell Health Cancer Institute, New Hyde Park, NY, as they discuss the current advances in radiotherapy for GI cancer.

    The post Developments in Radiotherapy for GI Cancer appeared first on VJOncology.

    Latest advances in early-stage breast cancer Aug 25, 2023

    Over the last decades, systemic therapy for patients with early-stage breast cancer has undergone remarkable enhancements, with the objectives and structures of neoadjuvant clinical trials continuously developing.

    In this podcast, we are joined by Sara Tolaney, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, Michael Gnant, MD, FACS, FEBS, Medical University of Vienna, Vienna, Austria, Hope S. Rugo, MD, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, Justin Balko, PharmD, PhD, Vanderbilt University Medical Center, Nashville, TN, as they discuss advances in early-stage HER2-positive, HR-positive and triple-negative breast cancer.

    The post Latest advances in early-stage breast cancer appeared first on VJOncology.

    Applications of AI in Oncology Aug 18, 2023

    Cancer plays a substantial role in worldwide mortality, accounting for approximately 9.3 million deaths each year. Despite considerable strides made over recent decades, the challenge of delivering personalized care persists. In an effort to mitigate this, the integration of artificial intelligence (AI) tools has been suggested across various realms within the field of oncology. The applications of AI in oncology encompass the refinement of cancer research methodologies, the enhancing of clinical protocols, gaining deeper insights into the intricate characteristics of tumors, and more.

    In this podcast, we hear from Manisha Palta, MD, Duke University, Durham, NC, Benoit Gallix, MD, PhD, American Hospital of Paris, Neuilly-sur-Seine, France, Andrew J. Armstrong, MD, MSc, Duke Cancer Institute, Durham, NC, David A. Mankoff, MD, PhD, Abramson Cancer Center, Philadelphia, PA, and Young Kwang Chae, MD, MPH, MBA, National Cancer Institute, Bethesda as they discuss current and future applications of AI in oncology.

    The post Applications of AI in Oncology appeared first on VJOncology.

    Targeted radionuclide therapy in prostate cancer Aug 11, 2023

    Prostate cancer stands as the most frequently detected malignant condition among men, ranking as the second primary contributor to cancer-linked fatalities in Western society. While localized prostate cancer can be addressed through various efficient treatments, nearly all patients eventually advance to the state of incurable metastatic castration-resistant prostate cancer. Given the substantial toll on both mortality and quality of life due to the disease’s progression, there exists a pressing demand for novel, precisely targeted therapeutic interventions.

    Targeted radionuclide therapy is an increasingly favored treatment option for prostate cancer, attributed to its ability to administer a greatly concentrated absorbed dose precisely to the intended tumor site, all the while safeguarding the neighboring healthy tissues.

    In this podcast, we hear from Jeremie Calais, MD, MSc, University of California, Los Angeles, CA, Scott Tagawa, MD, MS, FACP, Weill Cornell Medical Center, New York, NY, and Shahneen Sandhu, MBBS, FRACP, Peter MacCallum Cancer Centre, Melbourne, Australia, on some of the latest updates in targeted radionuclide therapy for prostate cancer.

    The post Targeted radionuclide therapy in prostate cancer appeared first on VJOncology.

    Latest updates in mesothelioma Aug 04, 2023

    In this latest episode from VJOncology, join us as we explore the latest news in mesothelioma research with three distinguished speakers. Anthony Chalmers, MD, University of Glasgow, Glasgow, UK, Dean Fennell, MBBS, PhD, FRCP, University Hospitals of Leicester NHS Trust, Leicester, UK, and Riyaz Shah, BSc(Hons), MBBS, FRCP, PhD, Kent Oncology Centre, UK. Discover the Phase II SYSTEMS-2 trial’s potential to reshape mesothelioma treatment and revolutionize patient care, unravel the excitement surrounding targeted therapy, particularly the TEAD inhibitor IK-930, showing great promise in disrupting cancer-promoting pathways, and finally learn more about the crucial role of immunotherapy in combating mesothelioma and its potential to offer new avenues for improved patient outcomes.

    The post Latest updates in mesothelioma appeared first on VJOncology.

    iwCAR-T Session V: Advances in head & neck and CNS cancers Jul 28, 2023

    The 5th International Workshop on CAR-T (iwCAR-T) took place in Scottsdale, AZ, on 14 – 16 April 2023, and brought together world-leading experts in CAR-T therapy as they discussed the latest in the field. In this podcast series, you will gain an insight into the sessions that took place at this year’s meeting, which covered the latest updates in CAR-T therapy in solid tumors, as well as associated challenges.

    In this episode, Kedar Kirtane, MD, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, Rizwan Romee, MD, Dana-Farber Cancer Institute, Boston, MA, and Jong Chul Park, MD, Massachusetts General Hospital, Boston, MA, share their insights on potential therapies for head and neck cancer, focusing on combination treatments and novel therapeutics. Topics discussed include the use of memory-like NK cells in combination with long-acting IL-15 and checkpoint inhibitors for enhanced efficacy, as well as the advantages of NK cell-based therapies over traditional T cell-based CAR treatments, including reduced side effects and increased responsiveness to tumor cells. In addition, the discussion explores strategies to overcome challenges, such as immune suppressive phenotypes and tumor microenvironments.

    The post iwCAR-T Session V: Advances in head & neck and CNS cancers appeared first on VJOncology.

    Highlights in GI cancer from ESMO WCGIC 2023 Jul 21, 2023

    The ESMO World Congress on Gastrointestinal Cancer (WCGIC) 2023 brought together world-renowned experts in oncology to present and discuss the latest advances in gastrointestinal cancer. In this podcast, we hear from leading healthcare professionals as they provide an overview of highlights from this year’s meeting. We will be joined by Philip Philip (Wayne State University School of Medicine/Henry Ford Health, Detroit, MI), Shouki Bazarbashi (King Faisal Specialist Hospital and Research Center-Riyadh, Riyadh, Saudi Arabia), and Anna Wagner (University of Lausanne, Lausanne, Switzerland).

    We will hear on the feasibility of precision medicine approaches in pancreatic cancer, as well as findings from the INNOVATION trial, which assessed chemotherapy with trastuzumab and pertuzumab in patients HER2-positive gastric cancer. Several colorectal trials will additionally be discussed, including VELO, DEEPER, IMPROVE and AVETRIC, which all assessed the feasibility of panitumumab or cetuximab in the metastatic setting.

    The post Highlights in GI cancer from ESMO WCGIC 2023 appeared first on VJOncology.

    Updates in immunotherapy for head and neck cancer Jul 14, 2023

    In this podcast we’ll be covering some of the latest updates in immunotherapy for head and neck cancer. Ezra Cohen, MD, FRCPSC, FASCO, Moores Cancer Center at UC San Diego Health, San Diego, CA, discusses the clinical activity of petosemtamab, a bispecific antibody targeting EGFR and LGR5, in patients with head and neck squamous carcinoma (HNSCC). Nabil Saba, MD, FACP, Winship Cancer Institute of Emory University, Atlanta, GA, presents findings from a Phase II trial (NCT03468218) of pembrolizumab and cabozantinib in patients HNSCC. Ari Rosenberg, MD, University of Chicago, Chicago, IL, describes the trial design of the Phase II DEPEND trial (NCT03944915), which assessed neoadjuvant nivolumab, paclitaxel, and carboplatin followed by response-stratified chemoradiation (CRT) in locoregionally advanced HPV-negative HNSCC. Blessie Elizabeth Nelson, MBBS, DMRT, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the ongoing study investigating the synergy between the potential efficacy of Clostridium novyi with pembrolizumab. Lastly, Heath Devin Skinner, MD, PhD, Hillman Cancer Center, Pittsburgh, PA, shares findings from the Phase II study (NCT03715946), which aimed to investigate treatment de-intensification for resected human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC) by adding nivolumab to a reduced radiation therapy (RT) regimen.

    The post Updates in immunotherapy for head and neck cancer appeared first on VJOncology.

    iwCAR-T session VI: Advances in GI cancers Jul 07, 2023

    The 5th International Workshop on CAR-T (iwCAR-T) took place in Scottsdale, AZ, on 14 – 16 April 2023, and brought together world-leading experts in CAR-T therapy as they discussed the latest in the field. In this podcast series, you will gain an insight into the sessions that took place at this year’s meeting, which covered the latest updates in CAR-T therapy in solid tumors, as well as associated challenges.

    In this engaging discussion, we are excited to be joined by three distinguished experts in the field of oncology, J. Randolph Hecht, MD, from UCLA Santa Monica Medical Center, Santa Monica, CA, who will chair this discussion, Diane Simeone, MD, from NYU Langone Health, New York City, NY, and Xianxin Hua, MD, PhD, from the University of Pennsylvania, Philadelphia, PA. Listen to uncover the cutting-edge techniques and novel strategies employed in CAR-T therapy, all intended to revolutionize the treatment landscape of GI cancers.

    The post iwCAR-T session VI: Advances in GI cancers appeared first on VJOncology.

    Highlights in bladder cancer at ASCO 2023: NORSE, RAGNAR, and THOR Jun 30, 2023

    In this episode, we will be covering highly anticipated updates in urothelial carcinoma presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023 in Chicago, IL. We are joined by Arlene Siefker-Radtke, MD of The University of Texas MD Anderson Cancer Center. Professor Siefker-Radtke is a leading expert in genitourinary cancer and will be sharing insights and updates from the ASCO 2023 Annual Congress, including a discussion of the NORSE (NCT03473743), THOR (NCT03390504), and RAGNAR (NCT04083976) trials. These trials investigated the use of the FGFR inhibitor, erdafitinib, in comparison or combination with other therapies.

    The post Highlights in bladder cancer at ASCO 2023: NORSE, RAGNAR, and THOR appeared first on VJOncology.

    ASCO 2023 Highlights: THOR, INDIGO and ADAURA Jun 23, 2023

    The American Society of Clinical Oncology Annual Meeting 2023 brought together thousands of experts in oncology to hear new data and discuss how to improve the diagnosis and treatment of patients with cancer. In this podcast, we hear from leading experts as they discuss some of the most groundbreaking trials from this year’s meeting. We will be joined by Yohann Loriot (Gustave Roussy, Villejuif, France), Karan Dixit (Northwestern Memorial Hospital, Chicago, IL), Roy S. Herbst (Yale School of Medicine, New Haven, CT), Ticiana Leal (Winship Cancer Institute of Emory University, Atlanta, GA), Jason Luke (University of Pittsburgh, Pittsburgh, PA).

    We will hear on the THOR study evaluating erdafitinib in metastatic urothelial cancer with FGFR alterations and the INDIGO trial of vorasidenib in residual or recurrent grade 2 glioma with an IDH1/2 mutation. There will also be discussion on the ADAURA trial investigating adjuvant osimertinib in resected EGFR‑mutated stage IB–IIIA non-small cell lung cancer, the LUNAR trial evaluating Tumor Treating Field therapy with standard of care in metastatic non-small cell lung cancer following platinum failure. The KEYNOTE-716 study, which assessed pembrolizumab in patients with high risk stage IIB or IIC cutaneous melanoma will also be discussed.

    The post ASCO 2023 Highlights: THOR, INDIGO and ADAURA appeared first on VJOncology.

    iwCAR-T Session III: CAR-T clinical advances in lung cancer Jun 16, 2023

    The 5th International Workshop on CAR-T (iwCAR-T) took place in Scottsdale, AZ, on 14 – 16 April 2023, and brought together world-leading experts in CAR-T therapy as they discussed the latest in the field. In this podcast series, you will gain an insight into the sessions that took place at this year’s meeting, which covered the latest updates in CAR-T therapy in solid tumors, as well as associated challenges.

    In this engaging discussion, we are honored to be joined by three distinguished experts in the field of oncology, Prasad Adusumilli, MD, FACS, from Memorial Sloan Kettering Cancer Center, New York, NY, Adam Schoenfeld, MD, also from Memorial Sloan Kettering Cancer Center, New York, NY, and William Go, MD, PhD, from A2 Biotherapeutics in Agoura Hills, California. Listen to gain a deep understanding of the cutting-edge approaches and novel strategies employed in CAR-T therapy, all aimed at revolutionizing the treatment landscape for lung cancer.

    The post iwCAR-T Session III: CAR-T clinical advances in lung cancer appeared first on VJOncology.

    iwCAR-T Session II: Cell therapies in GU cancers May 25, 2023

    The 5th International Workshop on CAR-T (iwCAR-T) took place in Scottsdale, AZ, on 14 – 16 April 2023, and brought together world-leading experts in CAR-T therapy as they discussed the latest in the field. In this podcast series, you will gain an insight into the sessions that took place at this year’s meeting, which covered the latest updates in CAR-T therapy in solid tumors, as well as associated challenges.

    Join Vivek Narayan, Saul Priceman, and Nicholas Zorko in this compelling podcast episode recorded during the iwCAR-T meeting. Focusing on genitourinary malignancies, particularly prostate and urothelial cancer, the experts discuss the promises and hurdles of NK cell therapies, unresolved questions surrounding NK cell infiltration and manufacturing as well as obstacles in engineering T cells for the immunologically cold environment of prostate cancer. Insights into the role of lymphodepletion chemotherapy and the advantages of targeting B7-h3 as an antigen in prostate cancer are also explored.

    The post iwCAR-T Session II: Cell therapies in GU cancers appeared first on VJOncology.

    iwCAR-T Session I: Emerging CARs and future challenges in solid tumors May 19, 2023

    The 5th International Workshop on CAR-T (iwCAR-T) took place in Scottsdale, AZ, on 14 – 16 April, 2023, and brought together world-leading experts in CAR-T therapy as they discussed the latest in the field. In this podcast series, you will gain an insight into the sessions that took place at this year’s meeting, which covered the latest updates in CAR-T therapy in solid tumors, as well as associated challenges.

    Today, experts Julian Molina (Mayo Clinic, Rochester, MN), Mathew Angelos (University of Pennsylvania, Philadelphia, PA), and Sebastian Kobold (Ludwig-Maximilians-University of Munich, Munich, Germany) bring you updates live from iwCART 2023. In considering the latest research and trials in the field of CAR T-cell therapy and the challenges associated with treating solid tumors, these specialists discuss using CAR macrophages in combination with other immunotherapies, manipulating the tumor microenvironment, the genetic engineering of CAR T-cells to add and/or remove specific factors, and tumor heterogeneity.

    The post iwCAR-T Session I: Emerging CARs and future challenges in solid tumors appeared first on VJOncology.

    Highlights at AACR 2023: mRNA vaccines in melanoma and novel RAF inhibitors May 09, 2023

    In this podcast, we’ll be covering highlights from the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL, including personalized mRNA and neoantigen vaccines, nivolumab with the standard of care in prostate cancer, and BGB-3245, a novel RAF dimer inhibitor, in solid tumors. Hear from Jeffrey Weber, NYU Langone Perlmutter Cancer Center, NY, Mansi Saxena, Icahn School of Medicine at Mount Sinai, New York, NY, John Michael Bryant, Moffitt Cancer Center, Tampa, FL, and Alison Schram, Memorial Sloan Kettering Cancer Center, New York, NY, who will all talk on these exciting advances.

    The post Highlights at AACR 2023: mRNA vaccines in melanoma and novel RAF inhibitors appeared first on VJOncology.

    Liquid biopsy in lung cancer: precision medicine and MRD Apr 28, 2023

    In this podcast, we’ll be discussing the use of liquid biopsy in lung cancer, with Professor Klaus Pantel of University Medical Center Hamburg-Eppendorf, in Hamburg, Germany. At the European Lung Cancer Congress (ELCC) 2023, we spoke with Professor Pantel about possible areas where liquid biopsy could be useful, such as clinical trial recruitment, as well as practical considerations for the use of liquid biopsies, and the role of MRD status in the management of non-small cell lung cancer.

    The post Liquid biopsy in lung cancer: precision medicine and MRD appeared first on VJOncology.

    St. Gallen highlights: controversies in the axilla Apr 14, 2023

    In this podcast, Icro Meattini (University of Florence, Florence, Italy) and Orit Kaidar-Person (Sheba Medical Center, Ramat Gan, Israel) discuss updates and controversies in the axillary management of breast cancer, live at the St Gallen Breast Cancer Consensus 2023.

    The post St. Gallen highlights: controversies in the axilla appeared first on VJOncology.

    Radiotherapy Highlights from ASCO GU 2023 with Sophia Kamran, Himanshu Nagar, and Neha Vapiwala Apr 06, 2023

    In this podcast, hear from GU cancer experts Sophia Kamran (Massachusetts General Hospital and Harvard Medical School, Boston, MA), Himanshu Nagar (Weill Cornell Medicine and New York Presbyterian, New York City, NY), and Neha Vapiwala (Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA) as they discuss the highlights in radiation oncology for GU cancers at the ASCO GU Cancers Symposium 2023.

    In prostate cancer, key radiation oncology trials included FORMULA-509 (NCT03141671), RADICALS-HD (NCT00541047), CHHiP, and PACE-A. In bladder cancer, hot topics of discussion included the use of adaptive radiotherapy and a debate on when to use bladder-only or whole-pelvis radiotherapy. Finally, in testicular cancer, a key discussion compared the use of radiotherapy vs surgery vs chemotherapy for the treatment of stage 2a seminoma.

    The post Radiotherapy Highlights from ASCO GU 2023 with Sophia Kamran, Himanshu Nagar, and Neha Vapiwala appeared first on VJOncology.

    Chemotherapy, post-adjuvant therapy, and clinical trial ethics at St Gallen BCC 2023 Mar 31, 2023

    The St Gallen Breast Cancer Congress took place on the 15-18 March 2023. Leading researchers and experts were brought together in Vienna, Austria, to discuss and debate the most important updates in breast cancer. In this podcast, we’ll run through research updates spanning from early treatment to post-adjuvant therapy and a taste of the ethical considerations involved in recruiting for clinical trials. We’ll be hearing from Prof. Philip Poortmans of AZ Sint-Augustinus – Oncologisch Centrum GZA, Dr Lisa Carey of UNC Lineberger Comprehensive Cancer Center, Dr Marleen Kok of the Netherlands Cancer Institute, Dr Hope S. Rugo of Helen Diller Family Comprehensive Cancer Center, Dr Sara Tolaney of Dana-Farber Cancer Institute, and Dr Orit Kaidar-Person of Sheba Medical Center, about new developments in our understanding of appropriate chemotherapy and immunotherapy options, as well as the importance of this conference in progressing clinical practice for breast cancer.

    The post Chemotherapy, post-adjuvant therapy, and clinical trial ethics at St Gallen BCC 2023 appeared first on VJOncology.

    Key Trials from ASCO GU 2023 with Scott Tagawa, Karie Runcie, and Tanya Dorff Mar 24, 2023

    In this episode, join GU cancer experts Scott Tagawa (Weill Cornell Medicine and New York Presbyterian, New York City, NY), Karie Runcie (Columbia University Irving Medical Center, New York City, NY), and Tanya Dorff (City of Hope Comprehensive Cancer Center, Duarte, CA) as they discuss the most important clinical trial data for prostate, bladder, and kidney cancer at the ASCO GU Cancers Symposium 2023.

    In prostate cancer, PARP inhibitors were a hot topic of discussion, with data from TALAPRO-2 (NCT03395197) and TRITON3 (NCT02975934) being presented. In bladder cancer, IMvigor130 (NCT02807636) and TROPHY-U-01 (NCT03547973) were two of the key trials, with additional discussions on antibody-drug conjugates (ADCs), nectin-4-targeted therapies, and the use of molecular profiling in clinical practice. Finally, in kidney cancer, there were updates from ZIRCON (NCT03849118), COSMIC-313 (NCT03937219), and CheckMate 9ER (NCT03141177).

    The post Key Trials from ASCO GU 2023 with Scott Tagawa, Karie Runcie, and Tanya Dorff appeared first on VJOncology.

    Biomarkers, patient selection, and immunotherapy at ESMO Gynae 2023 Mar 17, 2023

    In this episode, we’ll hear from Marcia Hall, Eric Pujade-Lauraine, and Mansoor Raza Mirza, who will share their expertise and insights on the latest developments in gynecological cancer research and treatment from ESMO Gynae 2023.

    First, we will hear about a study exploring the use of circulating tumor cells as a potential biomarker for predicting response to therapy. Dr Hall discusses how this study has the potential to revolutionize cancer treatment and diagnosis, and what the implications of these findings are for future research.

    Prof. Pujade-Lauraine updates us on the findings from the PAOLA-1 trial, which evaluated the use of maintenance olaparib plus bevacizumab in patients with ovarian cancer. He discuss the importance of patient selection in ovarian cancer, and how these updated findings can inform treatment decisions for patients.

    Finally, Dr. Mirza shares his insights on the potential of combination therapies, personalized medicine, and immunotherapy in the treatment of endometrial cancer. He discusses how these new approaches are changing the way we think about treatment, and what the future holds for patients with endometrial cancer.

    The post Biomarkers, patient selection, and immunotherapy at ESMO Gynae 2023 appeared first on VJOncology.

    Hot Topics in Renal Cell Carcinoma and Rare Tumors Mar 10, 2023

    In this podcast we’ll hear from experts in GU cancer on some of the most exciting clinical trial data in kidney cancer as well as some of the latest developments in rare tumors presented at the 2023 ASCO Genitourinary Cancers congress. We will be joined by Thomas Powles, MBBS, MRCP, MD, Barts Cancer Institute, London, UK, Michael Atkins, MD, Lombardi Comprehensive Cancer Center, Washington DC, Talal El Zarif, MD, Dana-Farber Cancer Institute, Boston, MA, Lucia Nappi, MD, University of British Columbia, Vancouver, Canada, Robert A. Huddart, PhD, FRCR, MRCP, MBBS, The Royal Marsden Hospital and The Institute of Cancer Research, London, UK.

    We will hear about outcomes by IMDC risk in the COSMIC-313 trial assessing cabozantinib plus nivolumab and ipilimumab and treatment-free survival outcomes of the HCRN G16-260 trial of nivolumab plus ipilimumab in advanced renal cell carcinoma. We’ll also discuss a longitudinal evaluation of plasma miR371 to detect minimal residual disease and early relapse of germ cell tumors and talk on the safety and efficacy of immune checkpoint inhibitors in penile squamous cell carcinoma, as well as the comparative cost-effectiveness of alternative imaging and surveillance schedules for testicular seminoma from the TRISST trial.

    The post Hot Topics in Renal Cell Carcinoma and Rare Tumors appeared first on VJOncology.

    Key data and hot topics in prostate cancer at ASCO GU 2023 Mar 03, 2023

    In this episode, we’ll be hearing from GU cancer experts about some of the biggest prostate cancer data presented at the ASCO Genitourinary Cancers Symposium 2023, including TRITON3, CheckMate650, and FORMULA-509. We’ll also be hearing perspectives on some of the hot topics in the field, such as treatment sequencing and combination therapies, unanswered questions for the use of PSMA PET in the staging of disease, and the use of active surveillance in localized prostate cancer.

    Join Alan Bryce, MD, Mayo Clinic, Rochester, MN, Russell Kent Pachynski, MD, Washington University School of Medicine, St. Louis, MO, Paul Nguyen, MD, Dana-Farber Cancer Institute, Boston, MA, Silke Gillessen, MD, Oncological Institute of Southern Switzerland, Bellinzona, Switzerland, David Nanus, MD, Weill Cornell Medicine and New York Presbyterian Hospital, New York City, NY, and Anthony Victor D’Amico, MD, PhD, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Boston, MA, as they discuss the latest developments in prostate cancer.

    The post Key data and hot topics in prostate cancer at ASCO GU 2023 appeared first on VJOncology.

    Hot Topics in Bladder Cancer at ASCO GU 2023 Feb 24, 2023

    In this podcast, we dive deep into some of the most exciting advances in bladder cancer research that were presented at the 2023 ASCO Genitourinary Cancers congress. We will hear from Kyle Rose, MD, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, Robert Huddart, PhD, FRCR, MRCP, MBBS, The Royal Marsden Hospital and The Institute of Cancer Research, London, UK, Aristotelis Bamias, MD, National and Kapodistrian University of Athens, Athens, Greece, and Andrea Necchi, MD, Vita-Salute San Raffaele University and IRCCS San Raffaele Hospital and Scientific Institute, Milan, Italy. We’ll be discussing some of the most highly anticipated clinical trials that were presented at the conference, including IMvigor130 and KEYNOTE-057. We’ll also explore the use of circulating cell-free DNA to detect minimal residual disease, as well as the potential of adaptive image-guided radiotherapy. Join us as we explore these hot topics in bladder cancer research and hear from the experts themselves about what these developments mean for the future of bladder cancer treatment.

    This podcast recording took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

    The post Hot Topics in Bladder Cancer at ASCO GU 2023 appeared first on VJOncology.

    Approaches to NSCLC with or without targetable mutations Feb 17, 2023

    In this podcast, we will explore approaches to non-small cell lung cancer
    (NSCLC) with and without targetable mutations. NSCLC is the most
    common type of lung cancer, and while significant strides have been
    made in its management, there are still areas of unmet need. Our
    speakers, Luis Raez, MD, FACP, FCCP, from Memorial Healthcare System in
    Pembroke Pines, FL, Melissa Johnson, MD, Sarah Cannon Research
    Institute, Nashville, TN, and Jorge Nieva, MD, from the University of
    California, San Francisco, CA, share the current treatment landscape for
    patients with NSCLC with and without targetable mutations, highlighting
    recent trial results, and challenges associated with sequencing of
    therapies.

    The post Approaches to NSCLC with or without targetable mutations appeared first on VJOncology.

    CAR-T in solid tumors: advances and challenges in targeting CLDN18.2, HER2 and STEAP 1 Feb 10, 2023

    Whilst CAR-T cell therapies have found considerable success in targeting hematological malignancies, major hurdles remain in the solid tumor space. Novel targets such as claudin 18.2 (CLDN18.2), and innovative strategies have led to encouraging results in solid tumors. In this podcast, we will hear from Gregory P. Botta, MD, PhD, UC San Diego Medical Center, San Diego, CA, Jon Amund Kyte, MD, PhD, University of Oslo, Oslo, Norway, Benjamin Schlechter, MD, Dana-Farber Cancer Institute, Boston, MA, and Andras Heczey, MD, Baylor College of Medicine, Houston, TX, as they share their expert insights in this ever-expanding field.

    The post CAR-T in solid tumors: advances and challenges in targeting CLDN18.2, HER2 and STEAP 1 appeared first on VJOncology.

    ASCO GI 2023: Bile duct cancer updates with Ghassan Abou-Alfa Feb 03, 2023

    In this episode, we are joined by Professor Ghassan Abou-Alfa of Memorial Sloan Kettering Cancer Center. Professor Abou-Alfa is a renowned expert in biliary tract cancer and will be sharing insights and updates from the ASCO GI Cancers Symposium 2023, including a discussion of the Phase II IMbrave 151 trial (NCT04677504). We will also hear an overview of the current state of clinical practice in the field of biliary tract cancer and thoughts on the use of molecular testing in this field.

    The post ASCO GI 2023: Bile duct cancer updates with Ghassan Abou-Alfa appeared first on VJOncology.

    Breast Cancer Sessions: Highlights from SABCS 2022 with Sara Tolaney, Paolo Tarantino & Sarah Sammons Jan 25, 2023

    The San Antonio Breast Cancer Symposium (SABCS) 2022 took place on the 6-10th of December 2022 in San Antonio, TX. Leading experts in breast cancer came together to hear the latest clinical trial data and discuss how to improve care for patients with breast cancer.

    In this podcast, we hear from Sara Tolaney, MD, MPH, Sarah Sammons, MD, and Paolo Tarantino, MD, of Dana-Farber Cancer Institute, Boston, MA, as they discuss the hot topics from SABCS 2022 in an exclusive roundtable discussion. Topics covered include updates on the use of the AKT inhibitor capivasertib, latest SERD data including elacestrant and camizestrant and other novel ER degraders, strategies post CDK4/6 inhibition, biomarkers for response to antibody-drug conjugates such as HER2-low and TROP-2, as well as updated progression-free survival results from DESTINY-Breast03.

    The Breast Cancer Podcasts on VJOncology are supported by Seagen. Seagen have no influence over the production of the content.

    The post Breast Cancer Sessions: Highlights from SABCS 2022 with Sara Tolaney, Paolo Tarantino & Sarah Sammons appeared first on VJOncology.

    Updates in cervical cancer Jan 20, 2023

    January is Cervical Cancer Awareness month, so for this podcast, we’ve collected the latest updates from our interviews with leading experts in cervical cancer.

    Dr Jamie Takayesu, MD, of the University of Michigan, Ann Arbor, MI, explains recent research into disparities in the assessment of sexual function of men and women undergoing radiotherapy for prostate cancer or cervical cancer. Professor Jyoti Mayadev, MD, of the University of California San Diego, San Diego, CA, takes us through the Phase III CALLA trial, which investigated durvalumab and chemoradiotherapy for cervical cancer. Finally, Dr Kamran Ahmed, MD, of Moffitt Cancer Center, Tampa, FL, explains interim results from a Phase II trial of atezolizumab and SBRT in advanced cervical cancer.

    The post Updates in cervical cancer appeared first on VJOncology.

    Resistance to immune checkpoint inhibitors in NSCLC Jan 13, 2023

    In this podcast, we’ll be covering the latest updates on immune checkpoint inhibitor resistance for patients with non-small cell lung cancer (NSCLC). We’ll be hearing from Professor Benjamin Besse, MD, Gustave Roussy Institute, Villejuif, France, Dr Kishu Ranjan, PhD, Yale School of Medicine, New Haven, CT, and Dr Biagio Ricciuti, MD, Dana-Farber Cancer Institute, Boston, MA, about new developments in our understanding of mechanisms of resistance, as well as possible therapeutic options for overcoming resistance.

    The post Resistance to immune checkpoint inhibitors in NSCLC appeared first on VJOncology.

    Impact of race on breast cancer outcomes Jan 06, 2023

    Breast cancer is one of the leading causes of cancer mortality, with incidence, pathology, and clinical outcomes varying by geographical distribution as well as different racial and ethnic populations. Black, compared to White women with localized breast cancer have higher mortality and worse distant recurrence-free survival, which is often attributed to social determinants of health and higher prevalence of triple-negative breast cancer in black patients. In addition, racial and ethnic diversity in breast cancer clinical trials is lacking with both Blacks and Hispanics underrepresented.

    In this podcast, we hear from Yara Abdou, MD, UNC School of Medicine, Chapel Hill, NC, Maja H. Oktay, MD, PhD, Montefiore Einstein Cancer Center, Bronx, NY, and Neelima Vidula, MD, Massachusetts General Hospital, Boston, MA, who discuss the impact of race on breast cancer outcomes, with respect to the RxPONDER trial, the role of the tumor microenvironment, as well as the impact of race on clinical, socioeconomic, and genomic characteristics, clinical trial participation, and receipt of genotype-matched therapy among patients with metastatic breast cancer.

    The Breast Cancer Podcasts on VJOncology are supported by Seagen. Seagen have no influence over the production of the content.

    The post Impact of race on breast cancer outcomes appeared first on VJOncology.

    Immunotherapy updates in GI cancer Dec 23, 2022

    Gastrointestinal (GI) cancers have a high incidence rate and is the leading cause of cancer-related mortality. Despite current combinational treatment strategies including chemotherapy, surgery, radiotherapy, and targeted therapies, survival rates remain markedly low for patients with advanced disease due to treatment resistance, rapid disease progression and metastasis, creating a strong urgency for the development of optimal therapeutic approaches. Immunotherapy is becoming increasingly established in the integrative management of GI cancers, with novel combinational strategies revolutionizing the treatment landscape and providing promise for patients with advanced stage disease.

    In this podcast we hear from Ghassan Abou-Alfa, MD, MBA, Memorial Sloan Kettering Cancer Center, New York, NY, Eran Ophir, PhD, Compugen Ltd., Tel Aviv, Israel, Michael Overman, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Andras Heczey, MD, Baylor College of Medicine, Houston, TX, and Mitchell Ho, PhD, National Institutes of Health, Bethesda, MD, on some of the latest immunotherapeutic strategies for treating GI cancers.

    The post Immunotherapy updates in GI cancer appeared first on VJOncology.

    Updates from ESMO Asia 2022 Dec 16, 2022

    The ESMO Asia 2022 congress took place on the 2nd to the 4th of December in Singapore. We heard from experts across Asia and Europe as they discussed the latest updates in oncology in the Asia-Pacific region.

    In this episode, we hear from Dr Tomohiro Matsuda on the epidemiology of rare cancers in Asia, Dr Avinash Khadela and Dr Annalisa Trama on how to improve outcomes for patients with head and neck cancer, and Dr Kohei Shitara, Dr Ken Kato, and Dr Teresa Macarulla on updates in gastrointestinal cancers.

    The post Updates from ESMO Asia 2022 appeared first on VJOncology.

    Updates in EGFR-mutant NSCLC Dec 02, 2022

    A large proportion of patients with non-small cell lung cancer (NSCLC) have mutations in EGFR, making it a popular target for novel therapeutics. In this podcast, we hear from Prof. Charles Swanton, Dr Emilia Lim, Prof. Sanjay Popat, Dr Qing Zhou, Dr Hazel O’Sullivan, Dr Julia Rotow, and Dr Biagio Ricciuti, as they discuss some of the latest clinical trial data in this field, as well as perspectives on molecular testing and new research into the causes of EGFR-mutant lung cancer.

    The post Updates in EGFR-mutant NSCLC appeared first on VJOncology.

    UKONS 2022: cancer care in the digital age Nov 25, 2022

    The UKONS Annual Conference took place on 11th and 12th November 2022 in Belfast, Ireland. Leading experts gave updates on the latest challenges in oncology nursing, with discussion around the conference theme ‘cancer care in the digital age’.

    In this podcast, we hear from UKONS President Mark Foulkes (Royal Berkshire NHS Foundation Trust) with an overview of the UKONS 2022 debate on in-person versus virtual consultations. We also speak with experts Catherine Oakley (Guys and St Thomas NHS Foundation Trust) and Jo Armes (University of Surrey) who give interesting perspectives on the impact of digital innovations in oncology nursing and hazardous occupational exposure to cytotoxic drugs.

    This podcast was recorded during the UK Oncology Nursing Society (2022) Annual Meeting held in Belfast, UK.

    The post UKONS 2022: cancer care in the digital age appeared first on VJOncology.

    Updates in immunotherapy from SITC 2022 Nov 18, 2022

    The 37th Annual Meeting of the Society for Immunotherapy in Cancer (SITC) took place on the 8th-12th of November 2022 in Boston, MA. Leading experts discussed practice-changing trial updates and the latest news in immune-oncology.

    In this podcast, we hear from Prof. Judith Varner (University of California, San Diego, CA) on the combination of myeloid cell and T-cell targeting as an effective anti-tumor strategy and Dr Saman Maleki (Western University, London, Canada) on microbiome modification with fecal transplant before immunotherapy to reduce primary resistance in melanoma. We also hear exciting clinical trial updates in microsatellite stable colorectal cancer (MSS CRC) from Prof. Michael Overman (The University of Texas MD Anderson Cancer Center, Houston, TX) and in melanoma from Dr Diwakar Davar (UPMC Hillman Cancer Center, Pittsburgh, PA).

    The post Updates in immunotherapy from SITC 2022 appeared first on VJOncology.

    Advances in radiotherapy from ASTRO 2022 Nov 16, 2022

    The ASTRO 2022 Annual Meeting took place on the 23-26th October 2022, in San Antonio, TX. Leading experts gave updates on clinical trials in radiotherapy, as well as discussing hot topics in the field.

    In this podcast, we hear from several experts in the field of radiotherapy as they update us on the biggest trials and points of discussion presented at ASTRO 2022, including results from the CALLA trial (NCT03830866), unmet needs and challenges in radiotherapy, and thoughts on how artificial intelligence can be used to advance cancer care.

    The post Advances in radiotherapy from ASTRO 2022 appeared first on VJOncology.

    Immunotherapy Updates in Head & Neck Cancer Nov 04, 2022

    Head and neck squamous cell carcinoma (HNSCC) is the most prevalent form of head and neck cancer and is typically associated with tobacco use and the human papillomavirus (HPV). Whilst this form of cancer has historically been associated with poor prognosis, the advent of checkpoint inhibitors such as pembrolizumab has increased overall survival in patients with PD-L1–expressing HNSCC.

    In this podcast, we will hear from Marcin Dzienis, MD, Gold Coast University Hospital, Southport, Australia, Jean-Pascal Machiels, MD, PhD, Cliniques Universitaires Saint-Luc, Brussels, Belgium, and Denis Soulieres, The Université de Montréal, Montréal, Canada, sharing their expert insights in this exciting field and the latest updates in the KEYNOTE-412 and KEYNOTE-B10 trials.

    The post Immunotherapy Updates in Head & Neck Cancer appeared first on VJOncology.

    Evolving role of ctDNA in breast cancer Oct 26, 2022

    With the advent of next-generation sequencing technologies, circulating tumor DNA (ctDNA) has now become an important player in the diagnosis, treatment, and management of breast cancer. In early breast cancer, the clearance of ctDNA is associated with improved pathological complete response following neoadjuvant therapy and may be important in treatment selection in patients with advanced disease. Continued efforts will likely lead to improvements in the use of liquid biopsy approaches and widespread routine clinical practice.

    In this podcast, we will hear from Oleg Gluz, MD, Evang. Krankenhaus “”Bethesda”” Klinik, Mönchengladbach, Germany, Marla Lipsyc-Sharf, MD, Dana-Farber Cancer Institute, Boston, MA, and Michail Ignatiadis, MD, PhD, Institut Jules Bordet who explore the use of ctDNA in breast cancer.

    The Breast Cancer Podcasts on VJOncology are supported by Seagen. Seagen have no influence over the production of the content.

    The post Evolving role of ctDNA in breast cancer appeared first on VJOncology.

    Updates in Immuno-Oncology from ITOC 2022 Oct 24, 2022

    The Immunotherapy of Cancer Conference (ITOC) 2022 brought together experts in the field of immuno-oncology to hear the latest findings and discuss how to advance oncology drug development and delivery.

    In this podcast, we hear from Prof. Mascha Binder (Martin-Luther-Universität Halle-Wittenberg, Halle, Germany) discussing whether it is beneficial to combine immunotherapy with chemotherapy and Professor Chong Xian (Harvard Medical School, Boston, MA) on the pan synergistic antitumor activity of pan-PI3K inhibition and immune checkpoint blockade in bladder cancer. We also hear from Professor Sebastian Kobold (Ludwig-Maximilians-Universität München, Munich, Germany), Thaddäus Strzalkowski (Ludwig-Maximilians-Universität München, Munich, Germany) and Florian Markle (Ludwig-Maximilians-Universität München, Munich, Germany) discussing various approaches to overcoming the challenges associated with CAR-T cells in solid tumors.

    The post Updates in Immuno-Oncology from ITOC 2022 appeared first on VJOncology.

    ESMO 2022: Updates in Sarcoma Oct 14, 2022

    The European Society for Medical Oncology Annual Meeting 2022 brought together thousands of experts in oncology to hear new data and discuss how to improve the diagnosis and treatment of patients with cancer.

    In this podcast, we hear from some of the leading experts in sarcoma, as they discuss the biggest trials and hot topics from the meeting.

    Tom Wei-Wu Chen (National Taiwan University Hospital, Taipei, Taiwan), discusses biomarker analyses from the LEADER (NCT03526679) trial, which investigated lenvatinib plus eribulin for patients with leiomyosarcoma and liposarcoma. Patrick Schöffski (KU Leuven, Leuven, Belgium) discusses recent advances in the management of soft tissue sarcoma (STS), and Erlinda Gordon (Cancer Center of Southern California/Sarcoma Oncology Center, Santa Monica, CA) explains the rationale of using the combination therapy of ipilimumab plus nivolumab plus trabectedin in the first-line for patients with advanced leiomyosarcoma. Lastly, Radwa Sharaf (Foundation Medicine Inc, Cambridge, MA) provides an overview of an investigation into genomic determinant of high telomeric content beyond the canonical ATRX/DAXX alterations in sarcoma.

    The post ESMO 2022: Updates in Sarcoma appeared first on VJOncology.

    GI Cancer Sessions: ESMO Highlights with Geoffrey Ku and Sam Klempner Oct 12, 2022

    Following an exciting day at the ESMO 2022 meeting in Paris, France, leading gastrointestinal cancer experts get together to share their highlights. Join Geoffrey Ku and Sam Klempner as they dissect key updates in upper GI cancer. Topics covered include updates from DESTINYGastric-02 (NCT04014075) and MOONLIGHT (NCT03647969), as well as discussions on the optimal use of immunotherapy for patients with upper GI cancers. We also hear about research into potential novel biomarkers that could help with overcoming the immunosuppressive tumor microenvironment.

    The post GI Cancer Sessions: ESMO Highlights with Geoffrey Ku and Sam Klempner appeared first on VJOncology.

    Breast Cancer Sessions: Highlights from ESMO 2022 with Elisa Agostinetto & Evandro de Azambuja Oct 10, 2022

    The European Society for Medical Oncology (ESMO) Annual Meeting, showcased an array of updates in breast cancer care and management, including updates on pivotal trials in the early and metastatic breast cancer settings.

    In this podcast, we hear from leading experts, Elisa Agostinetto and Evandro de Azambuja (Jules Bordet, Brussels, Belgium) who discuss the latest advances in breast cancer from ESMO 2022. In hormone receptor-positive HER2-negative breast cancer, overall survival results from the TROPiCS-02 study (NCT03901339) evaluating sacituzumab govetican, and MONARCH-3 (NCT02246621) investigating the addition of abemaciclib is discussed. In addition, findings from the DATA trial (NCT00301457), which evaluated whether extended adjuvant endocrine therapy was associated with significant benefit is discussed. In triple-negative breast cancer, the findings from SYNERGY (NCT03616886) and BELLINI (NCT03815890) trials are also considered, which aim to improve understanding of the role of immunotherapy in breast cancer.

    This discussion took place at the European Society for Medical Oncology (ESMO) 2022 Annual Meeting, in Paris, France.

    The post Breast Cancer Sessions: Highlights from ESMO 2022 with Elisa Agostinetto & Evandro de Azambuja appeared first on VJOncology.

    ESMO 2022: Updates in Colorectal Cancer Sep 30, 2022

    The European Society for Medical Oncology Annual Meeting 2022 brought together thousands of experts in oncology to hear new data and discuss how to improve the diagnosis and treatment of patients with cancer.

    In this podcast, we hear from some of the leading experts in colorectal cancer, as they discuss the biggest trials and hot topics from the meeting. Dr Sartore-Bianchi discusses overcoming acquired resistance to targeted therapy in colorectal cancer, and Dr Cremolini talks on the influence of sidedness on prognosis and treatment of metastatic colorectal cancer. We also hear from Dr Fang discussing EpCAM-targeted CAR T-cell therapy for advanced colorectal cancer and Dr Cohen on real-world evidence on ctDNA reliably predicting recurrence in resected colorectal cancer. Finally, Prof. Stintzing, Prof. Strickler and Dr Orlandi share key colorectal cancer trial updates presented at the meeting.

    The post ESMO 2022: Updates in Colorectal Cancer appeared first on VJOncology.

    ESMO 2022: Updates in Breast Cancer Sep 26, 2022

    The European Society for Medical Oncology Annual Meeting 2022 brought together thousands of experts in oncology to hear new data and discuss how to improve the diagnosis and treatment of patients with cancer.

    In this podcast, we hear from some of the leading experts in breast cancer, as they discuss the biggest trials and hot topics from the meeting. Dr Elisa Agostinetto discusses three of the biggest trials for metastatic breast cancer: TROPiCS02 (NCT03901339), MONARCH 3 (NCT02246621) and SYNERGY (NCT03616886). Prof. Fabrice Andre talks on the monarcHER trial (NCT02675231) and Dr Naoto Ueno explains the patient-reported outcome data from the DESTINY-Breast04 trial (NCT03734029).

    The post ESMO 2022: Updates in Breast Cancer appeared first on VJOncology.

    ESMO 2022 Daily Round-Ups: Day 4 Sep 12, 2022

    Catch up on our highlights from Day 4 of ESMO 2022!

    We spoke to Toni Choueiri, Erika Hamilton, Jonathan Rosenberg, and Charles Swanton, among many more! Keep an eye on VJOncology for more interviews, podcasts, and roundtable discussions throughout the congress.

    The post ESMO 2022 Daily Round-Ups: Day 4 appeared first on VJOncology.

    ESMO 2022 Daily Round-Ups: Day 3 Sep 12, 2022

    Catch up on our highlights from Day 3 of ESMO 2022!

    We spoke to Fabrice Andre, Fred Saad, and Solange Peters, among many more! Keep an eye on VJOncology for more interviews, podcasts, and roundtable discussions throughout the congress.

    The post ESMO 2022 Daily Round-Ups: Day 3 appeared first on VJOncology.

    ESMO 2022 Daily Round-Ups: Day 2 Sep 11, 2022

    Catch up on our highlights from Day 2 of ESMO 2022!

    We spoke to Dirk Schadendorf, Bjorn Henning Gronberg, Oleg Gluz, and Shaheenah Dawood, among many more! Keep an eye on VJOncology for more interviews, podcasts, and roundtable discussions throughout the congress.

    The post ESMO 2022 Daily Round-Ups: Day 2 appeared first on VJOncology.

    The Lung Cancer Sessions: Updates from WCLC 2022 Sep 02, 2022

    The Lung Cancer Sessions from VJOncology aim to provide interesting perspectives from leading experts on the big topics in lung cancer research.

    In this podcast, we hear from Lizza Hendriks of Maastricht University and Tiziana Vavala of the University of Turin as they discuss key updates from the IASLC World Congress on Lung Cancer in Vienna, Austria. Topics include the use of sotorasib in KRASG12C-mutant non-small cell lung cancer, oligometastatic disease, and key trial updates from the meeting.

    The post The Lung Cancer Sessions: Updates from WCLC 2022 appeared first on VJOncology.

    TILs, Cancer Vaccines & the Future of Cellular Therapies in Melanoma with Allison Betof Warner Aug 26, 2022

    Immunotherapy plays a vital role in the management of patients with advanced-stage melanoma, and more recently, adoptive cell therapies and cancer vaccines have shown to be viable, novel treatment approaches able to induce complete and durable remissions in patients with melanoma.

    In this exclusive podcast, VJOncology speaks to Allison Betof Warner, MD, PhD, from Memorial Sloan Kettering Cancer Center, New York, NY, who discusses the clinical potential of cellular therapies in the management of patients with melanoma, including the use of tumor-infiltrating lymphocyte (TIL) therapies as well as cancer vaccines and the next steps for these novel therapeutic approaches.

    The post TILs, Cancer Vaccines & the Future of Cellular Therapies in Melanoma with Allison Betof Warner appeared first on VJOncology.

    Updates in lung cancer from WCLC 2022 Aug 19, 2022

    The International Association for the Study of Lung Cancer (IASLC) held their World Congress in Lung Cancer (WCLC) in Vienna, Austria, on the 6-9th August 2022. The congress brought together leading experts in lung cancer from around the world, to hear practice-changing trial updates and discuss the best ways to improve care for patients.

    In this podcast, we hear from Dr Rachel Murray of Leeds Cancer Centre, UK, on the Yorkshire Enhanced Stop Smoking (YESS) study, and Professor Sanjay Popat from the Royal Marsden NHS Foundation Trust, UK, on the Phase III CALGB140503 trial. Professor Martin Reck, from the Lung Clinic Grosshansdorf, Germany, gave us an overview of some of the key trials presented at the congress, including JAVELIN, PRIMUS, NintNivo, IMpower010, and NADIM, and Dr David Baldwin of Nottingham University Hospitals NHS Trust, UK, talks on the impact of COVID-19 on lung cancer care and how the effects can be mitigated.

    The post Updates in lung cancer from WCLC 2022 appeared first on VJOncology.

    Updates in Checkpoint Inhibitors for Kidney Cancer Aug 12, 2022

    The advent of immune checkpoint inhibitors as a distinct class of immunotherapy has made a large impact within the field of oncology, providing a form of treatment that utilizes the host immune system to target the cancer. Immune checkpoint inhibitors regulate the immune system and prevent autoimmunity, with cytotoxic T lymphocyte-associated molecule-4 (CTLA-4), programmed cell death receptor-1 (PD-1), and programmed cell death receptor-1 ligand (PD-L1) being common targets for checkpoint inhibitors. Ipilimumab was the first FDA-approves checkpoint inhibitor and was indicated for patients with melanoma. Pembrolizumab and nivolumab, both PD-1 inhibitors, have been approved for renal cell carcinoma (RCC) and multiple clinical trials have demonstrated the potential of novel combination strategies.

    In this special podcast, leading genitourinary cancer experts Yousef Zakharia, MD, University of Iowa, Iowa City, IA, Pavlos Msaouel, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, and Michael Atkins, MD, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, discuss pivotal clinical trial data assessing pembrolizumab and nivolumab in clear-cell RCC as well as immune-related adverse events observed in patients receiving immune checkpoint inhibition therapy.

    The post Updates in Checkpoint Inhibitors for Kidney Cancer appeared first on VJOncology.

    iwCART Sessions: CAR-T clinical advances in breast and ovarian cancer Aug 05, 2022

    The International Workshop on CAR-T (iwCAR-T) 2022 featured many updates on the development of CAR-T therapies for the treatment of solid tumors. In this podcast, we hear from Jose Conejo-Garcia of Moffitt Cancer Center, Tampa, FL, and Jennifer Specht of Fred Hutchinson Cancer Research Center and the University of Washington, in Seattle, WA, as they discuss the latest CAR-T updates in breast cancer and ovarian cancer.

    The post iwCART Sessions: CAR-T clinical advances in breast and ovarian cancer appeared first on VJOncology.

    Clinical Applications of ctDNA in Oncology Jul 29, 2022

    Circulating tumor DNA (ctDNA) are small fragments of nucleic acid that are released into the circulating system via multiple mechanisms including apoptosis and necrosis, thereby reflecting the genomic landscape of the tumor from which it was derived. Due to its short half-life, ctDNA can facilitate in tracking the tumor burden in real-time, offering a valuable minimally invasive opportunity to monitor disease in individual cancer patients. Although not yet implemented in clinical practice, ctDNA has demonstrated potential clinical applications across all stages of cancer management, including in early diagnosis, identification of targetable genetic alterations, monitoring response to treatment and detection of minimal residual disease. Indeed, several studies have shown ctDNA to predict relapse significantly earlier than conventional clinical methods, thereby holding the potential to improve patient prognosis and survival outcomes.

    In this podcast, we spoke with Jeanne Tie, MBChB, FRACP, MD, Peter MacCallum Cancer Centre, Sanjay Popat, PhD, MBBS, FRCP, The Royal Marsden NHS Foundation Trust, London, UK, Miguel Garcia-Pardo, MD, Princess Margaret Cancer Center, Toronto, Canada, and Marla Lipsyc-Sharf, MD, Dana-Farber Cancer Institute, Boston, MA, who provide an overview of the applications of ctDNA in clinical practice and the remaining challenges yet to be overcome prior to its implementation in clinical practice.

    The post Clinical Applications of ctDNA in Oncology appeared first on VJOncology.

    iwCART Sessions: CAR-T clinical advances in lung cancer Jul 22, 2022

    The International Workshop on CAR-T (iwCAR-T) 2022 featured many updates on the development of CAR T-cell therapies for the treatment of solid tumors. This roundtable discussion on the development of cellular therapies in lung cancer was chaired by Melissa Johnson, MD from the Sarah Canon Research Institute and Tennessee Oncology, Nashville, TN, and featured Sandip Patel, MD,UC San Diego Health, San Diego, CA, Sylvia Lee, MD,Fred Hutchinson Cancer Research Center, Seattle, WA, and Prasad Adusumilli, MD, FACS, Memorial Sloan Kettering Cancer Center, New York, NY.

    In this session, alterations to the composition of the tumor microenvironment as a result of immune checkpoint therapy and the implications of this, as well as tumor-infiltrating lymphocyte (TIL) therapy for the treatment of solid tumours are discussed. This discussion was filmed during the International Workshop on CAR-t (iwCAR-T) held in Tampa, FL.

    The post iwCART Sessions: CAR-T clinical advances in lung cancer appeared first on VJOncology.

    ASCO 2022: Updates in Gastrointestinal Cancer Jul 15, 2022

    The American Society of Clinical Oncology Annual Meeting 2022 brought together thousands of experts in oncology to hear new data and discuss how to improve the diagnosis and treatment of patients with cancer.

    In this podcast, we hear from some of the leading experts in gastrointestinal cancer, as they discuss the biggest trials and hot topics from the meeting. For pancreatic cancer, we heard from Dr Vinod Balachandran about mRNA neoantigen vaccines and Prof. Rainer Fietkau about the CONKO-007 trial. Dr Ian Chau discussed the role of CAR T-cell therapies in the treatment of gastric cancer and gave us an update on CheckMate-648. For colorectal cancer, we heard from Dr Christine Parseghian about anti-EGFR rechallenge therapy, Dr Richard Kim about the KEYNOTE-651 trial, Prof. Jean-Pierre Gerard about the OPERA trial, and Prof. Chiara Cremolini and Dr Takayuki Yoshino the results and impact of the PARADIGM trial.

    The post ASCO 2022: Updates in Gastrointestinal Cancer appeared first on VJOncology.

    ASCO 2022: Updates in Genitourinary Cancer Jul 08, 2022

    The American Society of Clinical Oncology Annual Meeting 2022 brought together thousands of experts in oncology to hear new data and discuss how to improve the diagnosis and treatment of patients with cancer.

    In this podcast, we hear from some of the leading experts in genitourinary cancer, as they discuss the biggest trials and hot topics from the meeting. For prostate cancer, we hear from Prof. Arun Azad who explains the evolution of standard of care for patients with metastatic hormone-sensitive prostate cancer, Prof. Andrew Armstrong who gives us an update on the ARCHES trial, Dr Anis Hamid who discusses the use of circulating tumor cells in prostate cancer, Dr Clara Hwang who discusses how to overcome racial disparities in prostate cancer treatment, and Prof. Scott Tagawa and Dr Andrei Gafita discuss the use of PSMA-targeted radioligand therapies for prostate cancer, including updates from the VISION trial. For kidney cancer, we caught up with Dr Pavlos Msaouel about the results of a Phase I/II trial of sitravatinib and nivolumab in patients with clear cell renal cell carcinoma, as well as the key unmet needs in kidney cancer. Finally, for bladder cancer, we heard from Dr Joaquim Bellmunt about the latest updates from JAVELIN Bladder100 and Prof. Rob Jones about results from the cabozantinib arm of the ATLANTIS trial.

    The post ASCO 2022: Updates in Genitourinary Cancer appeared first on VJOncology.

    ASCO 2022: Updates in Breast Cancer Jul 01, 2022

    The American Society of Clinical Oncology Annual Meeting 2022 brought together thousands of experts in oncology to hear new data and discuss how to improve the diagnosis and treatment of patients with cancer.

    In this podcast, we hear from some of the leading experts in breast cancer, as they discuss the biggest trials and hot topics from the meeting. Dr Kevin Kalinsky gives an overview of the MAINTAIN and postMONARCHE trials, Prof. Lajos Pusztai discusses the KEYNOTE-522 trial, and Dr Erika Hamilton updates us on the DESTINY-Breast03 trial. We also hear from Dr Hamilton and Dr Hope Rugo on the practice-changing DESTINY-Breast04 results.

    The post ASCO 2022: Updates in Breast Cancer appeared first on VJOncology.

    ASCO 2022: Updates in Lung Cancer Jun 24, 2022

    The American Society of Clinical Oncology Annual Meeting 2022 brought together thousands of experts in oncology to hear new data and discuss how to improve the diagnosis and treatment of patients with cancer.trial

    In this podcast, we hear from some of the leading experts in lung cancer, as they discuss the biggest trials and hot topics from the meeting. Dr Narjust Duma discusses the key challenges faced by women with lung cancer, Dr Liza Villaruz, Dr Jia Luo, and Dr Joshua Sabari discuss recent updates in KRAS-mutated NSCLC, and Dr Matthew Krebs talks on the current state of genomic profiling for lung cancer patients in the UK. We also hear from Prof. Jarushka Naidoo, Dr Melissa Johnson, Dr Alessandra Bearz, and Dr Krebs on some of the key lung cancer trial data presented at the meeting.

    The post ASCO 2022: Updates in Lung Cancer appeared first on VJOncology.

    iwCAR-T Sessions: emerging CARs & challenges in solid tumors Jun 17, 2022

    This year’s International Workshop on CAR-T (iwCAR-T) featured a whole day on the development of CAR T-cell therapies in solid tumors. CAR T-cell therapy has revolutionized the treatment of patients with hematological malignancies however, application in solid tumors has historically seen limited success. In this discussion, Julian Molina, MD from the Mayo Clinic, Rochester, MN, Daniel Abate-Daga, MD, Moffit Cancer Center, Tampa, FL, and Daniel Wang, MD, City of Hope, Duarte, CA, discuss emerging CAR approaches in solid tumors including gamma-delta T-cells and induced pluripotent stem cells (iPSCs) as well as strategies to improve responses, increase persistence and minimize toxicity.

    This roundtable discussion was filmed in Tampa, FL during the iwCAR-T 2022 meeting.

    The post iwCAR-T Sessions: emerging CARs & challenges in solid tumors appeared first on VJOncology.

    ASCO 2022 Daily Round-Ups: Day 3 Jun 05, 2022

    Catch up on our highlights from Day 3 of ASCO 2022!

    We spoke to Jean-Pierre Gerard, Jonathan Rosenberg, Eva Segelov, Bruna Pellini, and Takayuki Yoshino, among many more! Keep an eye on VJOncology for more interviews, podcasts, and roundtable discussions throughout the congress.

    The post ASCO 2022 Daily Round-Ups: Day 3 appeared first on VJOncology.

    ASCO 2022 Daily Round-Ups: Day 2 Jun 04, 2022

    Catch up on our highlights from Day 2 of ASCO 2022!

    We spoke to Joaquim Bellmunt, Robert Jones, Miguel Garcia-Pardo, and Ian Chau, among many more! Keep an eye on VJOncology for more interviews, podcasts, and roundtable discussions throughout the congress.

    The post ASCO 2022 Daily Round-Ups: Day 2 appeared first on VJOncology.

    ASCO 2022 Daily Round-Ups: Day 1 Jun 04, 2022

    Catch up on our highlights from Day 1 of ASCO 2022!

    We spoke to Alexander Spira, Jia Luo, Paolo Ascierto, and Scott Tagawa, among many more! Keep an eye on VJOncology for more interviews, podcasts, and roundtable discussions throughout the congress

    The post ASCO 2022 Daily Round-Ups: Day 1 appeared first on VJOncology.

    Updates in radiation oncology from ESTRO 2022 May 27, 2022

    This year’s European Society for Radiotherapy and Oncology (ESTRO) annual congress took place in Copenhagen, Denmark, from 6-10 May 2022, and brought together leading experts from across the field of radiation oncology.

    In this podcast, we focus on some of the significant trial updates presented at the congress. We shall hear from Francesco Cortiula, MD, University Hospital of Udine, Udine, Italy, and Maastricht University Medical Center, Maastricht, Netherlands, Luca Nicosia, MD, IRCCS Sacro Cuore Don Calabria Hospital, Negrar, Italy, Tiuri Kroese, MD, University Medical Center Utrecht, Utrecht, Netherlands, Pedro Lara, MD, PhD, Fernando Pessoa Canarias University and San Roque University Hospital, Gran Canarias, Spain, and David Dearnaley, MA, MD, FRCP, FRCR, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK.

    The post Updates in radiation oncology from ESTRO 2022 appeared first on VJOncology.

    Breast Cancer Sessions: Treatment de-escalation in TNBC May 20, 2022

    The development of complex and effective therapies has improved outcomes in breast cancer, highlighting the need for strategies to escalate and de-escalate treatment. In this exclusive VJSession, Roberto Salgado, MD (GZA Ziekenhuizen Campus Sint-Augustinus, Wilrijk, Belgium) and Marleen Kok, MD (Netherlands Cancer Institute, Amsterdam, Netherlands) discuss the latest advances in triple-negative breast cancer (TNBC), including treatment de-escalation and associated biomarkers, as well as the emerging role of tumor-infiltrating lymphocytes (TILs).

    The Breast Cancer Podcasts on VJOncology are supported by Seagen. Seagen have no influence over the production of the content.

    The post Breast Cancer Sessions: Treatment de-escalation in TNBC appeared first on VJOncology.

    Trial updates from ESMO Breast Cancer 2022: TUXEDO-1, monarchE, KEYNOTE-355 May 16, 2022

    The European Society for Clinical Oncology (ESMO) Breast Cancer Conference was a hybrid event, held virtually and Berlin, Germany. This renowned meeting brought together global experts who disseminated the latest thinking in breast cancer.

    VJOncology had the opportunity to speak to Rupert Bartsch, Medical University Vienna, Vienna, Austria, Paolo Tarantino, Dana Farber Cancer Institute, Boston, MA, and Dave Cescon, Princess Margaret Cancer Centre, Toronto, Canada, who discussed the latest trial updates in breast cancer, including updates from the TUXEDO-1 (NCT04752059), monarchE (NCT03155997) and KEYNOTE-355 (NCT02819518) studies.

    The Breast Cancer Podcasts on VJOncology are supported by Seagen. Seagen have no influence over the production of the content

    The post Trial updates from ESMO Breast Cancer 2022: TUXEDO-1, monarchE, KEYNOTE-355 appeared first on VJOncology.

    Updates in GI cancers from AACR 2022 May 06, 2022

    This year’s American Association for Cancer Research (AACR) congress took place in New Orleans, LA, from 8-13 April 2022, and brought together leading experts from across the field of oncology. There were trial updates and presentations of real-world data, as well as discussions on the best ways to improve care for patients.

    In this podcast, we focus in on gastrointestinal cancers and hear from Michael Cecchini, from Yale School of Medicine, New Haven, CT, Zev Wainberg, MD, from University of California Los Angeles, Los Angeles, CA, and Pawel Kalinski, MD, PhD, from Roswell Park Comprehensive Cancer Center, Buffalo, NY, on the take-home messages from the congress.

    The post Updates in GI cancers from AACR 2022 appeared first on VJOncology.

    Expanding use of artificial intelligence (AI) in oncology Apr 29, 2022

    Improvements in early detection, diagnosis, and management have decreased cancer-related mortality, however, challenges associated with personalized care remain. Artificial intelligence (AI) combines computer science and robust datasets to enable problem-solving and has applications within the field of oncology.

    In this podcast, we hear from Ángel Alberich-Bayarri, PhD, QUIBIM – Quantitative Imaging Biomarkers in Medicine, Valencia, Spain, Matthijs Oudkerk, MD, PhD, University of Groningen, Groningen, Netherlands, and Cesare Piazza, MD, University of Brescia, Brescia, Italy, who discuss applications of AI in oncology, including diagnosis, screening and within radiomics.

    The post Expanding use of artificial intelligence (AI) in oncology appeared first on VJOncology.

    The evolving role of nurses amidst global pandemic: perspectives, and highlights from cancer nursing leaders Apr 22, 2022

    In a world that is still acclimatizing to the COVID-19 pandemic, the fragility of many aspects of our society has been laid bare. Global health care systems were among the most seriously affected by the SARS-CoV-2 which has put a spotlight on the integral role of nurses not only in day-to-day patient care and running of healthcare facilities but also in public education and awareness campaigns, public health policymaking, and population-based medicine.

    In this podcast, we hear from two oncology nursing leaders at the International Conference on Cancer nursing 2022 (ICCN), which took place virtually this year. Patsy Yates, AM, PhD, RN, FACN, FAAN, Queensland University of Technology, Brisbane, Australia, speaks on challenges experienced during the pandemic and positive initiatives that have arisen as a result. Stella Aguinaga Bialous, RN, DrPH, FAAN, University of California San Francisco School of Nursing, San Francisco, CA, advocates for the nursing community to embrace their influence on public health policy. We also catch up with Sarah Hargreaves, PhD, University of Sheffield, Sheffield, UK, who discusses findings from a survey on the impact of COVID-19 on lung cancer and mesothelioma nurses during the British Thoracic Oncology Group (BTOG) Conference 2022.

    The post The evolving role of nurses amidst global pandemic: perspectives, and highlights from cancer nursing leaders appeared first on VJOncology.

    The GU Cancer Sessions: Prostate & kidney cancer at ASCO GU 2022 Apr 11, 2022

    In this podcast, we hear from genitourinary (GU) cancer experts Tian Zhang, MD, Duke Cancer Center, Durham, NC, and Scott Tagawa, MD, MS, FACP, Weill Cornell Medicine, New York City, NY, as they discuss some of their highlights in prostate and kidney cancer research presented at the 2022 ASCO GU Cancers Symposium, held in San Francisco, CA.

    Listen to learn about the latest clinical research and practice-changing advances in GU cancers, including results from the Phase III PROpel and MAGNITUDE trials evaluating PARP inhibitors in patients with metastatic prostate cancer, as well the Phase III ARASENS trial studying darolutamide in combination with androgen deprivation therapy (ADT) and docetaxel.

    In renal cell carcinoma (RCC), the panel also discuss data from a Phase I/II trial evaluating axitinib in combination with nivolumab, the study of neoadjuvant avelumab and axitinib in localized clear-cell RCC in the Phase II NEOAVAX trial, as well as adjuvant pembrolizumab monotherapy in KEYNOTE-564.

    The post The GU Cancer Sessions: Prostate & kidney cancer at ASCO GU 2022 appeared first on VJOncology.

    Lung Cancer Screening: Current state and future directions Apr 01, 2022

    Lung cancer is one of the most common cancers in the world, and has a very low survival rate, partly due to many patients being diagnosed only once their disease has reached an advanced stage. Screening programmes for high-risk populations are a possible solution to this problem, as it would help to identify more lung cancer cases when they are in early stages, and are therefore more treatable.

    In this podcast, we explain the current guidelines from the US, UK, and Europe, talk on key trials in lung cancer screening, and hear from leading experts about possible future screening methods.

    The post Lung Cancer Screening: Current state and future directions appeared first on VJOncology.

    Novel treatment approaches in HR+/HER2- breast cancer Mar 25, 2022

    Resistance to endocrine therapy in patients with hormone-receptor positive (HR+), HER2-negative breast cancer inevitably results in relapse and metastasis, leading to death. Understanding mechanisms of intrinsic and acquired resistance has been the focus of many clinical studies. Recent advances including the use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors and phosphoinositide 3-kinase (PI3K) inhibitors have improved progression-free survival and overall survival in these patients, however, endocrine resistance still develops in some patients. New classes of agents including oral selective estrogen receptor degraders (SERDs) and CDK7 inhibition have been explored in advanced HR+/HER2- metastatic breast cancer.

    In this podcast, we hear from Aditya Bardia, MD, MPH, Massachusetts General Hospital, Boston, MA, Mario Campone, MD, PhD, Cancérologie de l’Ouest, René Gauducheau, St Herblain, France, and Charles Coombes, MD, PhD, Imperial College London, London, UK, as they discuss the latest data evaluating oral SERDs, elcacestrant and amcenestrant, as well as the CDK7 inhibitor, samuraciclib.

    The Breast Cancer Podcasts on VJOncology are supported by Seagen. Seagen have no influence over the production of the content.

    The post Novel treatment approaches in HR+/HER2- breast cancer appeared first on VJOncology.

    New treatment approaches for advanced or metastatic urothelial carcinoma Mar 18, 2022

    Clinical trials presented at the the American Society of Clinical Oncology (ASCO) Genitourinary Cancers (GU) Symposium 2022 have been investigating treatment options for patients with advanced or metastatic UC who are ineligible for or have progressed on platinum-based chemotherapy, in hopes of improving patient prognosis. The LEAP-011 trial explored the addition of the VEGFR inhibitor, lenvatinib, to first-line pembrolizumab for patients ineligible for platinum-based chemotherapy, in hopes of increasing responsiveness to pembrolizumab. The TROPHY-U-01 trial investigated treatment with sacituzumab govitecan for patients with mUC who had progressed on platinum-based chemotherapy and ICIs. The ATLANTIS trial is exploring personalized maintenance treatment options for patients undergoing palliative chemotherapy in biomarker-defined subgroups of patients with advanced UC.

    In this podcast, Yohann Loriot, MD, PhD, Gustave Roussy, Villejuif, France, and the University of Paris-Saclay, Gif-sur-Yvette, France, Petros Grivas, MD, PhD, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA and Simon Crabb, PhD, MBBS, Southampton Experimental Cancer Medicine Centre, University of Southampton, Southampton, UK, outline results from these clinical trials.

    The post New treatment approaches for advanced or metastatic urothelial carcinoma appeared first on VJOncology.

    The Breast Cancer Sessions: Highlights from SABCS 2021 Mar 11, 2022

    The San Antonio Breast Cancer Symposium (SABCS) 2021 saw ground-breaking data and developments in breast cancer being presented and in this special podcast, leading breast cancer experts Hope Rugo (UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA) and Dave Cescon (Princess Margaret Cancer Center, Toronto, Canada), dissect the latest advances in the field and offer their unique perspectives.

    Listen to this insightful roundtable discussion to learn about the latest clinical trial data in breast cancer, including pivotal developments from the KEYNOTE-522 and KEYNOTE-355 trials, which assessed pembrolizumab in triple-negative breast cancer. Developments in antibody-drug conjugates (ADCs) and the role of oral selective estrogen receptor degraders (SERDs) including elacestrant, following findings from EMERALD trial, are additionally examined.

    The post The Breast Cancer Sessions: Highlights from SABCS 2021 appeared first on VJOncology.

    The GI Cancer Sessions: Highlights from ASCO GI 2022 Mar 04, 2022

    In this episode of the VJOncology podcast, a panel of leading gastrointestinal (GI) cancer experts offer their perspectives on the key GI cancer data presented at the 2022 ASCO GI Cancers Symposium, held in San Francisco, CA, in January 2022.

    In this podcast, Nataliya Uboha, MD, PhD, University of Wisconsin, Madison, WI, is joined by Ghassan Abou-Alfa, MD, MBA, Memorial Sloan Kettering Cancer Center, New York, NY, and Kristen Ciombor, MD, MSci, Vanderbilt University Medical Center, Nashville, TN.

    Listen to learn about the latest clinical research and practice-changing advances in GI cancers, including the evaluation of durvalumab plus GemCis in biliary tract cancer in the TOPAZ-1 trial, how the HIMALAYA study compares to IMbrave150 in hepatocellular carcinoma and the assessment of adagrasib in KRAS G12C-mutated pancreatic ductal adenocarcinoma in KRYSTAL-1. In addition, the panel will be considering the implementation of circulating tumor DNA (ctDNA) testing in clinical practice for GI cancers following recent results from the CIRCULATE-Japan study, how the ACCENT IDEA study could change practice in stage III colorectal cancer, as well as advances in PD-1 blockade in MSI-high rectal cancer.

    The post The GI Cancer Sessions: Highlights from ASCO GI 2022 appeared first on VJOncology.

    Prostate Cancer Highlights from ASCO GU 2022 Feb 25, 2022

    The ASCO Genitourinary (GU) Cancers Symposium took place on the 17-19th February 2022, in San Francisco, CA. Leading experts gave updates on trials in prostate cancer, urothelial carcinoma, renal cell carcinoma, and rare GU cancers, as well as discussing hot topics in the field.

    In this podcast, we hear from several experts in the field of prostate cancer, as they update us on some of the biggest trials presented at ASCO GU 2022, including PROpel (NCT03732820), MAGNITUDE (NCT03748641), PRESIDE (NCT02288247), and ARASENS (NCT02799602). These four trials are investigating two ‘hot’ areas in prostate cancer research – PARP inhibitors and androgen receptor (AR) antagonists.

    The post Prostate Cancer Highlights from ASCO GU 2022 appeared first on VJOncology.

    Updates on HER2-positive breast cancer Feb 15, 2022

    HER2-positive breast cancer accounts for 15-20% of all breast cancer cases. It was associated with a poor prognosis until the approval of trastuzumab, a monoclonal antibody targeting HER2. Since then, the therapeutic landscape for patients with HER2-positive tumors has changed dramatically, with the introduction of other monoclonal antibodies such as pertuzumab, tyrosine kinase inhibitors including lapatinib and neratinib, and the antibody-drug conjugate trastuzumab emtansine (T-DM1). Currently, patients with HER2-positive breast cancer are treated with a taxane plus trastuzumab in the first-line setting and with T-DM1 in second-line. Several treatments are emerging as viable options for the third-line setting and beyond. Nevertheless, recent highly promising data from clinical trials investigating novel triple combinations such as tucatinib+trastuzumab+capecitabine, and trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate, has already started reshaping standard of care treatments for HER2-positive breast cancer.

    In this exclusive podcast, Rupert Bartsch, MD, of Medical University Vienna, Vienna, Austria, Javier Cortés, MD, PhD, Vall d’Hebron University Hospital, Barcelona, Spain, and Wolfgang Janni, MD, PhD, of Ulm University, Ulm, Germany, discuss the latest research updates in HER2-positive breast cancer therapy, sharing data from the practice-changing HER2CLIMB (NCT02614794) and DESTINY-Breast03 (NCT03529110) trials.

    The Breast Cancer Podcasts on VJOncology are supported by Seagen. Seagen have no influence over the production of the content.

    The post Updates on HER2-positive breast cancer appeared first on VJOncology.

    BTOG 2022: Highlights in lung cancer Feb 11, 2022

    For patients with lung cancer, surgical resection is a treatment option and perioperative management is imperative to improve surgical outcomes. Patients undergoing surgery may face a decline in quality of life, especially those who have co-morbidities or are older. Prehabilitation aims to prepare patients mentally and physically before surgery with exercise, nutrition and stress reduction. Whilst an optimal program is still under investigation, initial research has demonstrated the efficacy of prehabilitation, with patients requiring shorter hospital stays and having fewer post-operative complications.

    In this podcast, Matthew Evison, MD, University Hospital of South Manchester NHS Foundation Trust, Manchester, UK; Alastair Greystoke, PhD, MBChB, PhD, MRCP, University of Newcastle & Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK; and Neal Navani, MA, MRCP, MSc, PhD, Care Quality Improvement Department, Royal College of Physicians, London, UK, discuss the most current advances in the field of lung cancer. Topics include prehabilitation in lung cancer care, the process of understanding a next-generation sequencing (NGS) report, and the increasing role of low dose CT scanning. This interview took place at the 20th Annual British Thoracic Oncology Group (BTOG) Conference 2022.

    The post BTOG 2022: Highlights in lung cancer appeared first on VJOncology.

    The multidisciplinary use of ctDNA in gastrointestinal cancers Feb 02, 2022

    Gastrointestinal (GI) cancer remains one of the leading cause of global cancer mortality. The current standard for diagnosing GI cancers via biopsy is costly and invasive, as well as lacking in reliability. As such, these methods are not used for screening and the majority of GI cancers are diagnosed in the advanced stages of cancer progression, when curative surgery is inadequate and patients must resort to other forms of treatment. When discovered and treated in the early stages, there is a much greater chance of curing GI cancers.

    Circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) are biomarkers that are released from the tumor into the plasma of patients. These liquid biopsies offer a non-invasive method for the screening and early diagnosis of GI cancers, holding the potential to improve survival rates for this patient population.

    In this podcast, Scott Kopetz, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, Naureen Starling, BSc, FRCP, MD, The Royal Marsden NHS Foundation Trust, London, UK and Justin Mencel, MBBS, The Royal Marsden NHS Foundation Trust, London, UK, discuss the use of ctDNA to screen for GI cancer, and the use of CTCs in determining minimal residual disease, including for the detection of microscopic amounts of disease following surgery.

    The post The multidisciplinary use of ctDNA in gastrointestinal cancers appeared first on VJOncology.

    SITC 2021: Updates on the use of cellular therapies in solid tumors Jan 19, 2022

    Cellular immunotherapy approaches have proven to be highly effective in the treatment of patients with hematological malignancies over recent years. In contrast, the efficacy of cellular immunotherapy in solid tumors has been restricted due to a limited array of tumor-specific antigens to differentiate cancer cells from normal cells.

    In this podcast, we spoke with three leading experts in cellular immunotherapy who delineate the methods being used to overcome the challenges faced in targeting solid tumors. Join Julian Molina, MD, PhD, Mayo Clinic, Rochester, MN, Jeffrey S. Miller, MD, University of Minnesota, Minneapolis, MN, and Alexander Kamb, PhD, A2 Biotherapeutics, Agoura Hills, CA for a discussion of chimeric antigen receptor (CAR)-T cell approaches in the BASECAMP-1 study, pluripotent stem cell (iPSC)- derived NK cells to treat glioblastoma and the use of the Tmod™ (T-cell module) platform, which involves utilization of activating and inhibitory receptors to specifically target solid tumors.

    This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.

    The post SITC 2021: Updates on the use of cellular therapies in solid tumors appeared first on VJOncology.

    Breast Cancer Sessions: Highlights from SABCS 2021 with Lisa Carey & Aleix Prat Jan 14, 2022

    The San Antonio Breast Cancer Symposium 2021 featured exciting developments in early and advanced breast cancer, basic science, and translational research.

    In this podcast, we had the opportunity to hear from Lisa A. Carey (UNC Lineberger, Chapel Hill, NC) and Aleix Prat (Hospital Clínic Barcelona, Barcelona, Spain) who discuss advances in breast cancer care and management, including highlights from the meeting, as well as recent updates from the MONALEESA studies.

    The Breast Cancer Podcasts on VJOncology are supported by Seagen. Seagen have no influence over the production of the content.

    The post Breast Cancer Sessions: Highlights from SABCS 2021 with Lisa Carey & Aleix Prat appeared first on VJOncology.

    Immunotherapy updates from SABCS 2021 with Heather McArthur & Kevin Kalinsky Jan 04, 2022

    The success of immunotherapy in the treatment of solid tumors has created hope for its potential in breast cancer. The San Antonio Breast Cancer Symposium 2021 showcased an array of updates in breast cancer care and management, including updates on pivotal trials evaluating the use of immunotherapy in breast cancer.

    In this podcast, we hear from leading experts, Kevin Kalinsky (Emory University, Atlanta, GA) and Heather McArthur (UT Southwestern Medical Center, Dallas, TX) who discuss the latest advances in immunotherapy for breast cancer presented at the hybrid SABCS 2021 meeting and what the latest research means for the clinic.

    The Breast Cancer Podcasts on VJOncology are supported by Seagen. Seagen have no influence over the production of the content.

    The post Immunotherapy updates from SABCS 2021 with Heather McArthur & Kevin Kalinsky appeared first on VJOncology.

    The Lung Cancer Sessions: Advances in EGFR-mutated NSCLC Nov 25, 2021

    The Lung Cancer Sessions from VJOncology aim to provide interesting perspectives from leading experts on the big topics in lung cancer research. In this podcast, Ross Camidge, MD, PhD, of University of Colorado, Aurora, CO, chairs a lively discussion on the latest advances and standard clinical practices in EGFR-mutated NSCLC, including EGFR testing, options for first-line treatment, and developments in immunotherapy.

    He is joined by Rosario Garcia Campelo, MD, of Coruña University Hospital, A Coruña, Spain, Natasha Leighl, MD, MMSc, FRCPC, of Princess Margaret Cancer Center, Toronto, Canada, and Alexander Spira, MD, PhD, FACP, of Virginia Cancer Specialists, Fairfax, VA.

    The post The Lung Cancer Sessions: Advances in EGFR-mutated NSCLC appeared first on VJOncology.

    ISLB 2021: Current standards and future directions for liquid biopsy Nov 12, 2021

    Liquid biopsy is an exciting field, with many promising advances in recent years. In this podcast, we cover a range of possible uses of liquid biopsy throughout all stages of patient care, from early diagnosis and screening to post-treatment monitoring. We also discuss some of the key challenges that need to be overcome and think about the future of liquid biopsy research.

    We are joined by four speakers from the International Society of Liquid Biopsy (ISLB) Virtual Meeting 2021, Professor David Gandara, from UC Davis Comprehensive Cancer Center in Sacramento, California, Professor Natasha Leighl, from the Princess Margaret Cancer Center in Toronto, Canada, Professor Heinz Josef Lenz, from the University of Southern California, in Los Angeles, California, and Professor Catherine Alix-Panabieres from the University Medical Center of Montpellier in France.

    The post ISLB 2021: Current standards and future directions for liquid biopsy appeared first on VJOncology.

    Prostate Cancer Highlights from ESMO 2021 with Robert Jones Oct 28, 2021

    The European Society for Medical Oncology (ESMO) 2021 Congress saw many exciting clinical trials presented from across the field of oncology, some of which are paving the way for new standards of care for patients. Among the biggest readouts for the field of prostate cancer were the STAMPEDE (NCT00268476), PEACE-1 (NCT01957436), and ARCHES (NCT02677896) studies. In this podcast, we are joined by Robert Jones, MD, PhD, from the University of Glasgow and Beatson West of Scotland Cancer Centre, Glasgow, UK, as he provides an overview of the biggest news in prostate cancer from ESMO 2021.

    The post Prostate Cancer Highlights from ESMO 2021 with Robert Jones appeared first on VJOncology.

    The GU Cancer Sessions: Bladder Highlights from ESMO 2021 Oct 19, 2021

    VJOncology has assembled a group of leading genitourinary cancer experts to examine and discuss the latest developments in bladder cancer presented at the European Society for Medical Oncology (ESMO) 2021 Annual Meeting.

    Listen to this insightful roundtable discussion featuring Laurence Albiges, Gustave Roussy Institute, Villejuif, France, and Enrique Grande, MD Anderson Cancer Center Madrid, Madrid, Spain, to hear about ground-breaking erdafitinib data from NORSE in metastatic or locally advanced urothelial carcinoma, as well as VESPER in muscle-invasive bladder cancer (MIBC). They additionally examine innovative data on pembrolizumab in combination with anti- Ephrin-B2 sEphB4-HSA in advanced urothelial carcinoma.

    The post The GU Cancer Sessions: Bladder Highlights from ESMO 2021 appeared first on VJOncology.

    The Skin Cancer Sessions: Highlights from ASCO 2021 Oct 07, 2021

    VJOncology has assembled a panel of world-renowned skin cancer experts to examine and discuss the exciting advances in skin cancer presented at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting.

    In this exclusive podcast, James Larkin, MD, PhD, Royal Marsden Hospital, London, UK, is joined by Rodabe Amaria, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Ana Arance, MD, PhD, Hospital Clínic de Barcelona, Barcelona, Spain, and Paolo Ascierto, MD, National Tumor Institute, Milan, Italy.

    Listen to this insightful roundtable discussion to learn about the latest clinical trial data in skin cancer, including updates in adjuvant pembrolizumab in the KEYNOTE-054 and S1404 trials, as well as neoadjuvant ipilimumab plus nivolumab in OpACIN-neo trial. Additional topics of discussion include long-term follow-up in the CheckMate 067 and COLUMBUS trials, relatlimab plus nivolumab in RELATIVITY-047, lenvatinib in the anti-PD-1 refractory space in LEAP-004, and much more.

    The post The Skin Cancer Sessions: Highlights from ASCO 2021 appeared first on VJOncology.

    The Lung Cancer Sessions: Highlights from ASCO 2021 Oct 07, 2021

    Following the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting, VJOncology brought together a group of leading lung cancer experts to offer their perspectives on the latest research advances presented at the meeting and how they could impact lung cancer care in the future.

    In this exclusive post-ASCO podcast, Melissa Johnson, MD, Sarah Cannon Research Institute, Nashville, TN, is joined by Lizza Hendriks, MD, PhD, Maastricht University, Maastricht, Netherlands, and Heather Wakelee, MD, Stanford University, Stanford, CA, as they delve into the latest practice-changing lung cancer data.

    Listen to this esteemed panel discuss adjuvant trials including IMpower010, CTONG1103 and IMPACT, as well as biomarkers of response. The panel also cover targeted therapies including KRAS inhibitors such as sotorasib, HER3-directed antibody-drug-conjugates, as well as the treatment of lung cancer with EGFR exon 20 insertions.

    The post The Lung Cancer Sessions: Highlights from ASCO 2021 appeared first on VJOncology.

    The GI Cancer Sessions: Highlights from ASCO 2021 Oct 07, 2021

    At the virtual 2021 American Society of Clinical Oncology (ASCO) 2021 Annual Meeting, important advances and potentially practice-changing trial data were presented in a range of gastrointestinal (GI) malignancies such as esophageal, gastric and colorectal cancer. VJOncology has assembled an esteemed panel of leading GI experts to discuss the latest exciting developments, what these advances could actually mean for clinical practice in the future and what still needs to be done.

    Tobias Arkenau, MD, PHD, Sarah Cannon Research Institute UK, London, UK, chairs this roundtable discussion and is joined by:

    • Deborah Mukherji, MBBS, FRCP, American University of Beirut Medical Center, Beirut, Lebanon
    • Kai-Keen Shiu, FRCP, PhD, University College London Hospitals NHS Foundation Trust, London, UK
    • Lizzy Smyth, MD, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
    • Nataliya Uboha, MD, PhD, University of Wisconsin, Madison, WI
    • Susanna Ulahannan, MD, MMEd, University of Oklahoma, Oklahoma City, OK.

    In this GI Cancer Session podcast, you will learn about the results of the CheckMate 648 and RATIONALE 302 trials in esophageal cancer, as well as key gastric cancer studies, including KEYNOTE-811 and MAHOGANY. The panel also offer their perspectives on the study of first-line FOLFOXIRI plus cetuximab or bevacizumab in patients with RAS wild-type metastatic colorectal cancer in the DEEPER trial, and colorectal cancer maintenance therapy in the PanaMa and FOCUS4 trials. The panel also consider the use of Nal-IRI in biliary tract and pancreatic cancers, as well as promising data on emerging therapies such as trastuzumab deruxtecan, an anti-HER2 antibody-drug-conjugate, in metastatic colorectal cancer from the DESTINY-CRC01 trial.

    The post The GI Cancer Sessions: Highlights from ASCO 2021 appeared first on VJOncology.

    Key clinical trial data in urothelial carcinoma at ASCO 2021 Sep 10, 2021

    Chemotherapy is central to the treatment of advanced or metastatic urothelial carcinoma (UC), and platinum-based treatments, like cisplatin, have been the first-line treatment options for many years. To address the limitations of platinum-based chemotherapeutics, additional therapeutics have become available in more recent years for first- and second-line use. Specifically, for patients who are cisplatin-ineligible or those who relapse, immune checkpoint inhibitors, such as avelumab, pembrolizumab, and atezolizumab, targeting the program cell death 1 protein (PD-1) or its ligand (PD-L1), have gained FDA approval. Latest clinical trials have also combined immunotherapy drugs with novel therapies, like the antibody-drug conjugate enfortumab vedotin, to demonstrate high response rates; this has instigated further studies into comparison with platinum-based chemotherapeutics. Evidence of disruption to the fibroblast growth factor receptor (FGFR) signaling pathway in UC has also resulted in multiple studies investigating FGFR inhibitors, like rogaratinib, as a potential treatment option for patients with UC.

    In this deep dive, American Society of Clinical Oncology (ASCO) 2021 presenters Petros Grivas, MD, PhD, University of Washington School of Medicine & Fred Hutchinson Cancer Research Center, Seattle, WA; Terence W. Friedlander, MD, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; and Jonathan E. Rosenberg, MD, Memorial Sloan Kettering Cancer Center, New York, NY, will be sharing their insights into the latest advancements in immunotherapy for advanced urothelial carcinoma. Our experts will present the latest data from the JAVELIN Bladder 100, EV-103, and FORT-2 trials.

    The post Key clinical trial data in urothelial carcinoma at ASCO 2021 appeared first on VJOncology.

    Prostate Cancer Highlights from ASCO 2021 with Pedro Barata Aug 23, 2021

    This year, at the American Society of Clinical Oncology (ASCO) Virtual Meeting 2021, experts came together virtually to present and discuss the latest findings in oncology.

    In this podcast, Pedro Barata, MD, MSc Tulane University School of Medicine, New Orleans, LA, discusses highlights from the meeting. He focuses on the results from four Phase III trials assessing various therapies for the treatment of prostate cancer. Dr Barata begins with VISION (NCT03511664), examining the addition of lutetium-177 to standard of care treatment in progressive metastatic prostate cancer, followed by PEACE-1 (NCT01957436), investigating abiraterone and prednisone ± radiotherapy for hormone-naïve metastatic patients. He continues by highlighting Peace III (NCT02194842), a trial investigating enzalutamide and radium-223 combination therapy in asymptomatic or mildly symptomatic castration-resistance patients and concludes by talking about the SWOG S1216 study (NCT01809691), examining androgen deprivation therapy plus TAK-700 in patients with hormone-sensitive prostate cancer.

    This interview took place at the American Society of Clinical Oncology (ASCO) Virtual Meeting 2021.

    The post Prostate Cancer Highlights from ASCO 2021 with Pedro Barata appeared first on VJOncology.

    The Breast Cancer Sessions: Highlights from ASCO 2021 Aug 18, 2021

    VJOncology has assembled an international panel of leading breast cancer experts to discuss the latest advances and data from the virtual American Society of Clinical Oncology (ASCO) 2021 Annual Meeting.

    In this podcast, Erika Hamilton, MD, Sarah Cannon Research Institute, Nashville, TN, is joined by Giuseppe Curigliano, MD, University of Milan, Milan, Italy, Sara Tolaney, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, and Andrew Tutt, MBChB, PhD, The Institute of Cancer Research, London, UK, to examine the recent major breakthroughs in breast cancer and what they mean for clinical practice.

    Tune in to hear the expert panel offer their perspectives on adjuvant olaparib and the results of the OlympiA trial, capecitabine in the ECOG study, the GeparNuevo trial which looked at adding durvalumab to chemotherapy in patients with TNBC, as well as first-line paclitaxel plus durvalumab for TNBC in the BEGONIA trial. The panel also discuss the latest data for CDK4/6 inhibitors, SERDs and BCL-2 inhibitors, the use of talazoparib in the neoadjuvant setting and much more.

    The post The Breast Cancer Sessions: Highlights from ASCO 2021 appeared first on VJOncology.

    The GU Cancer Sessions: Bladder and Kidney Highlights from ASCO 2021 Aug 18, 2021

    During the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting, an exciting array of advances in genitourinary (GU) cancer research were presented. VJOncology has brought together a panel of leading GU experts to consider and debate the latest developments in bladder and kidney cancer and offer their perspectives on how they could impact patient care in the future.

    This post-ASCO GU cancer roundtable discussion is chaired by Elizabeth Plimack, MD, MS, from the Fox Chase Cancer Center, Philadelphia, PA, who is joined by Rana McKay, MD, University of California San Diego, San Diego, CA, and Thomas Powles, MBBS, MRCP, MD, Barts Cancer Institute, London, UK.

    Listen to this podcast to learn about the latest research in immunotherapy for the treatment of muscle-invasive bladder cancer and the exciting recent developments in bladder-sparing approaches. The panel also discuss groundbreaking adjuvant pembrolizumab data from KEYNOTE-564 in renal cell carcinoma (RCC) and how it will change their clinical practice in the future. In addition, we hear about updated results from the CLEAR trial, KEYNOTE-426, as well as alternative approaches in treating advanced RCC such as using the probiotic CBM588 in conjunction with immunotherapy.

    The post The GU Cancer Sessions: Bladder and Kidney Highlights from ASCO 2021 appeared first on VJOncology.

    ASCO 2021: Immunotherapy updates in lung cancer Aug 04, 2021

    Various immunotherapies including checkpoint inhibitors have emerged as effective treatment options for patients with non-small cell lung cancer (NSCLC). Immune checkpoints proteins such as PD-1, PD-L1 and CTLA-4 have become potential targets, as they have an immunosuppressive function and are overexpressed in certain cancers. Several checkpoint inhibitors have already received FDA approval including nivolumab and ipilimumab, and ongoing research is being conduced to assess novel therapies and combination regimens.

    In this podcast, Heather Wakelee, MD, Stanford University, Stanford, CA, David Spigel, MD, Sarah Cannon Research Institute, Nashville, TN, and Bruna Pellini, MD, Moffitt Cancer Center, Tampa, FL discuss results from the IMpower010 trial (NCT02486718), which assessed the anti-PD-L1 monoclonal antibody atezolizumab in non-small cell lung cancer (NSCLC), as well as the PACIFIC trial (NCT02125461), which investigated durvalumab in unresectable stage III NSCLC. The evolving field of checkpoint inhibitors in NSCLC and combining checkpoint inhibitors with cell therapies are also discussed. This interview took place at the American Society of Clinical Oncology (ASCO) Virtual Meeting 2021.

    The post ASCO 2021: Immunotherapy updates in lung cancer appeared first on VJOncology.

    EAU 2021: updates in testicular cancer Jul 28, 2021

    Whilst advances in diagnostic procedures, radiotherapies, cisplatin-based chemotherapy, and surgery have meant that testicular cancer is curable in around 95% of cases, the side effects of radiotherapy and chemotherapy can significantly impact quality-of-life (QoL) outcomes for patients treated for testicular cancer in both the short and long term. Currently, much research is investigating how novel approaches to treatment and monitoring can be used and incorporated to improve QoL outcomes for patients treated for testicular cancer.

    In this podcast, Tahlita Zuiverloon, MD, PhD, of the Erasmus MC Cancer Institute, Rotterdam, The Netherlands; Peter Albers, MD, University of Düsseldorf, Düsseldorf, Germany; and Matthew Murray, MB, BChir, PhD, Cambridge University Hospitals NHS Foundation Trust, discuss key updates in the field of testicular cancer, as presented at the 2021 European Association of Urology (EAU) Virtual Meeting, including research on the use of MRI versus CT, surgery in metastatic disease and microRNA biomarkers.

    The post EAU 2021: updates in testicular cancer appeared first on VJOncology.

    Highlights from ESMO WCGIC 2021: VALENTINO, KEYNOTE-811 & BEACON-CRC Jul 15, 2021

    The ESMO World Congress on Gastrointestinal Cancer (WCGIC) 2021 annual meeting took place virtually this year and leading experts came together to present on the most recent developments in GI cancer.

    In this podcast, Paolo Manca, MD, Istituto Nazionale dei Tumori Milano, Milano, Italy, Yelena Janjigian, MD, Memorial Sloan Kettering Cancer Center, New York, NY, and Dan Aderka, MD, Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel, discuss results from the VALENTINO (NCT02476045), KEYNOTE-811 (NCT03615326), and BEACON-CRC (NCT02928224) trials. Both the VALENTINO and KEYNOTE-811 trials investigated the use of monoclonal antibodies with chemotherapy in colorectal and gastric cancer respectively, whereas the BEACON-CRC trial assessed the effects of first-line bevacizumab in BRAF V600E-mutant metastatic colorectal cancer.

    This interview took place at the virtual ESMO World Congress on Gastrointestinal Cancer (WCGIC) 2021 annual meeting.

    The post Highlights from ESMO WCGIC 2021: VALENTINO, KEYNOTE-811 & BEACON-CRC appeared first on VJOncology.

    What’s new? Treating breast cancer with brain metastases Jul 13, 2021

    Metastatic breast cancer is breast cancer that has spread to other regions of the body, most commonly the liver, brain, bones, or lungs. Although significant developments have been made in the treatment options available for patients with metastatic breast cancer, the occurrence of brain metastases remains a substantial clinical challenge.

    The incidence and prognosis of patients with brain metastases related to breast cancer varies by subtype. Triple negative disease has the highest rates, occurring in as many as 46% of cancers, compared to 35% and 14% in HER2-positive and hormone receptor (HR)-positive disease, respectfully. Brain metastases are not only associated with poor prognosis, but can also cause neurological defects, through their effect on the cognitive and sensory functions of the brain. Ongoing research into the biology of metastases and increasing clinical trial inclusion are paving the way for discovery of new treatment strategies to achieve long-lasting efficacy against brain metastases.

    In this exclusive podcast, Erika Hamilton, of the Sarah Cannon Research Institute at Tennessee Oncology, Nashville, TN; Guy Jerusalem of the University of Liège, Belgium; Erica Michelle Stringer-Reasor, of the University of Alabama at Birmingham, AL; and Gaio Griguolo, of the Veneto Institute of Oncology, Padova, Italy, discuss the latest updates in metastatic breast cancer treatment.

    The Breast Cancer Podcasts on VJOncology are supported by Seagen. Seagen have no influence over the production of the content.

    The post What’s new? Treating breast cancer with brain metastases appeared first on VJOncology.

    Global breast cancer care Jul 13, 2021

    Healthcare systems around the world differ in financial and political situations. Therefore, it is vital to implement a global outlook of breast cancer care that focuses on applying access to high-quality practices, especially in low- and middle-income countries, where breast cancer remains a public health crisis.

    During this podcast, Andre Ilbawi, MD, of the World Health Organization (WHO), Carol Benn, MBBCh, FCS, of the Breast Care Center of Excellence, Milpark Hospital in Johannesburg, South Africa, and Cynthia Villareal-Garza, MD, DSc, of the Mexican National Cancer Institute & Tecnologico de Monterrey, Mexico discuss the latest information on global breast cancer care and specific practices within South Africa and Mexico.

    The Breast Cancer Podcasts on VJOncology are supported by Seagen. Seagen have no influence over the production of the content.

    The post Global breast cancer care appeared first on VJOncology.

    Latest developments in immunotherapy for patients with melanoma Jul 01, 2021

    Surgery is an effective treatment for non-metastatic melanoma, however, advanced melanoma demands additional intervention, such as chemotherapy or immunotherapy. The development of immunotherapies for melanoma has significantly improved outcomes for patients with metastatic cancer. Several immunotherapies for metastatic melanoma have already received FDA approval, including nivolumab and ipilimumab, and research is ongoing to develop new combination regimens to improve treatment safety and efficacy.

    In this podcast, Evan J. Lipson, MD, of the John Hopkins Medical Institute in Baltimore, James Larkin, PhD, FRCP, of The Royal Marsden NHS Foundation Trust in London, and Omid Hamid, MD, of The Angeles Clinic and Research Institute in Los Angeles, discuss key updates on immunotherapies for the treatment of melanoma, as presented at the 2021 ASCO Virtual Meeting.

    The post Latest developments in immunotherapy for patients with melanoma appeared first on VJOncology.

    ASCO 2021: PSMA-targeted radionuclide therapy for prostate cancer Jun 25, 2021

    Prostate-specific membrane antigen (PSMA) is overexpressed in more than 80% of prostate cancer tumors, making it a promising diagnostic and therapeutic target. Given the highly limited expression of PSMA outside of the prostate, precision approaches that specifically target PSMA have been of substantial interest in the field.

    PSMA-targeted radionuclide therapy combines a PSMA ligand with a radioactive compound that inhibits tumor cell growth and replication through induction of DNA damage. Early data assessing radiolabeled monoclonal antibodies against PSMA demonstrated some efficacy against prostate tumors but were hindered by poor tumor permeability and slow blood clearance. More recent investigations have assessed radiolabeled small molecules that show more promise. Evidence to date highlights radionuclide therapy as an exciting new option for metastatic castration-resistant prostate cancer, an area of high unmet need for new targeted treatment options.

    In this deep dive into the latest in PSMA-targeted radionuclide therapy, Karim Fizazi, MD, PhD, Institut Gustave Roussy, and Scott Tagawa, MD, MS, Weill Cornell Medical College, discuss results from the VISION trial of 177Lu-PSMA-617 and a Phase I/II study of 225Ac-J591, as well as the future of PSMA-targeted agents and important unanswered questions.

    The post ASCO 2021: PSMA-targeted radionuclide therapy for prostate cancer appeared first on VJOncology.

    The Lung Cancer Sessions: Highlights from BTOG 2021 Jun 22, 2021

    VJOncology has assembled a panel of leading experts, who offer their perspectives on the latest developments in lung cancer presented at the 19th British Thoracic Oncology Group (BTOG) Annual Conference 2021.

    In this podcast, Sanjay Popat, BSc, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust London, UK, is joined by Samreen Ahmed, MBBS, MSc(onc), FRCP, MD, University Hospitals of Leicester Trust, Leicester, UK, David Gilligan, MBChB, FRCPE, FRCR, Addenbrooke’s & Papworth Hospitals, Cambridge, UK and Neal Navani, MBBS, PhD, University College London Hospitals NHS Foundation Trust, London, UK.

    Tune in to hear the expert panel discuss the key learnings from the 19th BTOG Annual Conference, as they offer their perspectives on the impact of the COVID-19 pandemic on lung cancer care and managing patients with malignant pleural effusions. The panel also discusses the latest developments in novel KRAS inhibitors and antibody-drug conjugates (ADCs), radiotherapy in the adjuvant setting and the role of neoadjuvant checkpoint inhibitor therapies.

    The post The Lung Cancer Sessions: Highlights from BTOG 2021 appeared first on VJOncology.

    ESMO Breast 2021: updates on immunotherapy Jun 10, 2021

    Breast cancer is the most common type of cancer in women. Although most cases of early-stage non-metastatic disease are curable with surgery, effective treatments for later-stage and metastatic disease remain an unmet need. Several immunotherapies have received FDA approval for the treatment of breast cancer, including pembrolizumab, atezolizumab and trastuzumab deruxtecan.

    In this podcast, Rebecca Dent, MD, FRCP, of the National Cancer Centre Singapore, Rupert Bartsch, MD, of the Medical University of Vienna in Austria, and Marleen Kok, MD, PhD, of the Netherlands Cancer Institute in Amsterdam, discuss key updates on immunotherapies for the treatment of breast cancer, as presented at the 2021 ESMO Breast Cancer Virtual Meeting.

    The Breast Cancer Podcasts on VJOncology are supported by Seagen. Seagen have no influence over the production of the content.

    The post ESMO Breast 2021: updates on immunotherapy appeared first on VJOncology.

    The GU Cancer Sessions: Bladder and Kidney Highlights from ASCO GU 2021 May 14, 2021

    VJOncology has assembled a panel of leading experts, who offer their perspectives on the latest bladder and kidney cancer data presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancer Symposium, which was held virtually in February 2021.

    In this podcast, Arlene Siefker-Radtke, MD, University of Texas MD Anderson Cancer Center, Houston, TX, is joined by Alison Birtle, MRCP, FRCR, MD, Lancashire Teaching Hospitals, Preston, UK, Andrea Apollo, MD, National Cancer Institute, Bethesda, MD, and Thomas Powles, MBBS, MRCP, Barts Cancer Institute, London, UK.

    Tune in to learn more about the latest clinical trial data in genitourinary cancer, including updates from EV-301, evaluating enfortumab vedotin versus chemotherapy in patients with urothelial cancer, and CheckMate 274, studying adjuvant nivolumab for high-risk bladder cancer patients. The panel also discuss findings from the POUT trial for perioperative chemotherapy in upper tract urothelial cancer and investigations into combinations of cabozantinib, nivolumab and ipilimumab in all GU tumors. The panel share their insights on these exciting trial updates and debate how these advances will translate into multidisciplinary care for patients with genitourinary cancers.

    The post The GU Cancer Sessions: Bladder and Kidney Highlights from ASCO GU 2021 appeared first on VJOncology.

    Sequencing HER2-targeting therapies in the metastatic breast cancer space May 14, 2021

    Treatment approaches in breast cancer are multimodal, and with the onset of novel immunotherapies and targeted agents, the therapeutic landscape of patients with advanced disease has expanded. In HER2+ disease, the treatment landscape has become saturated with novel HER2-targeting agents, bringing into question how these agents should be sequenced for maximum benefit to patients.

    In this podcast, we spoke with three leading experts in breast cancer who discuss the optimal sequencing of HER2-targeted therapies such as T-DM1, neratinib, tucatinib, and margetuximab. Join Lisa Carey, MD, The University of North Carolina at Chapel Hill, Chapel Hill, NC, Hope Rugo, MD, FASCO, University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, and Thomas Bachelot, MD, PhD, Centre Léon Bérard, Lyon, France, who outline decision making in the metastatic HER2+ breast cancer space, as well as how to sequence these novel agents.

    The Breast Cancer Podcasts on VJOncology are supported by Seagen. Seagen have no influence over the production of the content.

    The post Sequencing HER2-targeting therapies in the metastatic breast cancer space appeared first on VJOncology.

    Latest news in GU: CAR-T in RCC, updates from IMvigor130, & liquid biopsies in prostate cancer May 13, 2021

    The American Association for Cancer Research Annual Meeting 2021 (AACR) took place virtually this year and showcased an array across the spectrum of cancer research, from cancer biology to translational studies and trial updates.

    In this podcast, we hear from three leading experts in genitourinary cancer and their insights from the AACR annual meeting. Yufei Wang, PhD, Dana-Farber Cancer Institute, Boston, MA, Enrique Grande, MD, of the MD Anderson Cancer Center Madrid, Madrid, Spain, and, Arpit Rao, MD, University of Minnesota, Minnesota, MN, talk on the development of a dual-targeted CAR T-cell evaluated in clear cell renal cell carcinoma, the latest overall survival data from IMvigor130 (NCT02807636), investigating atezolizumab in untreated metastatic urothelial carcinoma, and the clinical utility of liquid biopsies in prostate cancer.

    This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.

    The post Latest news in GU: CAR-T in RCC, updates from IMvigor130, & liquid biopsies in prostate cancer appeared first on VJOncology.

    The GU Sessions: Prostate Cancer Highlights from ASCO GU 2021 May 13, 2021

    The 2021 American Society of Clinical Oncology (ASCO) Genitourinary Cancer Symposium showcased a range of exciting clinical trial data and major milestones in prostate cancer. VJOncology has bought together a team of leading experts in prostate cancer to explore their insights on key updates from this meeting.

    In this exclusive podcast, Neal Shore, MD, FACS, Carolina Urologic Research Center, SC was joined by Bertrand Tombal, MD, PhD, Cliniques Universataires Saint-Luc, Brussels, Belgium, Rana McKay, MD, UC San Diego Health, CA, and Robert Jones, MBChB, PhD, University of Glasgow & Beaston West of Scotland Cancer Center, Glasgow, UK.

    The panel engage in an insightful discussion on the updated results from the ACIS trial in metastatic CRPC, as well as final analyses of the landmark Phase III SPARTAN, PROSPER and ARAMIS studies in non-metastatic CRPC. In addition, the panel debate the findings from the Phase III PROfound trial evaluating the PARP inhibitor olaparib and offer their perspectives on GnRH receptor antagonists, PSMA-PET and the integration of genomic profiling into practice.

    The post The GU Sessions: Prostate Cancer Highlights from ASCO GU 2021 appeared first on VJOncology.

    BTOG 2021: KRAS targeting and oncogenically-driven lung cancer May 12, 2021

    Traditional treatments for lung cancer include chemotherapy, radiotherapy and surgery, however the identification of oncogenic drivers, such as EGFR, ALK and ROS1, offers the potential for novel targeted therapies and personalized approaches to lung cancer treatment. Numerous studies and trials are underway which are investigating therapies targeting oncogenes including KRAS, PD-1/PD-L1 and JAK2, however, targeting of these genes and pathways has presented many challenges.

    In this podcast Colin Lindsay, BSc, MBChB, MRCP, PhD, of the Christie NHS Foundation Trust, Manchester, UK, and Samreen Ahmed, FRCP, MD, of University Hospitals of Leicester, Leicester, UK, discuss the history of KRAS-targeting and the latest updates in the treatment of oncogenically-driven lung cancer, as presented at the British Thoracic Oncology Group’s 19th Annual Conference, which took place virtually.

    The post BTOG 2021: KRAS targeting and oncogenically-driven lung cancer appeared first on VJOncology.

    The Breast Cancer Sessions: a focus on the St. Gallen Consensus Apr 26, 2021

    At the 17th St. Gallen International Breast Cancer Conference 2021, leading experts gathered virtually to take part in the renowned St. Gallen International Consensus Session on the optimal treatment of early breast cancer.

    In this podcast, St. Gallen Consensus Session Co-Chair Giuseppe Curigliano, MD, PhD, European Institute of Oncology & University of Milan, Milan, Italy, is joined by consensus panelists Lisa Carey, MD, FASCO, The University of North Carolina at Chapel Hill, NC, Hope Rugo, MD, FASCO, University of California, San Francisco, CA, and Fatima Cardoso, MD, Champalimaud Clinical Center, Lisbon, Portugal.

    Tune in to hear the expert panel discuss the key takeaways from the consensus session and the remaining challenges in early breast cancer care. They offer their perspectives on the role of pathologic complete response (pCR) in the post-neoadjuvant setting, gene signature assays for chemotherapy in pre- and post-menopausal women, neoadjuvant treatment in triple-negative and HER2-positive breast cancer, as well as the role of CDK4/6 inhibitors in the adjuvant setting.

    The post The Breast Cancer Sessions: a focus on the St. Gallen Consensus appeared first on VJOncology.

    Predictive and prognostic biomarkers in breast cancer Apr 07, 2021

    Following a breast cancer diagnosis, the most immediate challenges in patient management are the determination of prognosis and identification of the most appropriate adjuvant systemic therapy, the most valid of these tests include Oncotype DX and MammaPrint. In the identification of new predictive and prognostic markers, research efforts are focusing on the clinical utility of circulating and tumor DNA as well as the predictive significance of tumor-infiltrating lymphocytes (TILs).

    In this exclusive podcast, VJOncology spoke with Judy Garber, MD, MPH, of the Dana-Farber Cancer Institute, Boston, MA, Martine Piccart, MD, PhD, of the Université Libre de Bruxelles, Brussels, Belgium, and Sherene Loi, MBBS, PhD, FRACP, FAHMS from the Peter MacCallum Cancer Centre at the University of Melbourne, Melbourne, Australia, who outline the role of genetic testing in patients with breast cancer, genomic predictors of response and how a greater understanding of genomics can inform treatment approaches.

    The Breast Cancer Podcasts on VJOncology are supported by Seagen. Seagen have no influence over the production of the content.

    The post Predictive and prognostic biomarkers in breast cancer appeared first on VJOncology.

    The Lung Cancer Sessions: highlights from IASLC WCLC Feb 18, 2021

    VJOncology has assembled an international panel of leading experts in lung cancer and mesothelioma to bring you the key highlights from the IASLC World Conference on Lung Cancer (WCLC), which was held virtually in January 2021.

    Daniel Tan (National Cancer Centre Singapore, Singapore) is joined by Melissa Johnson (Sarah Cannon Research Institute, TN) and Dean Fennell (University Hospitals of Leicester NHS Trust, UK), who offer their perspectives on the exciting data and what research could change practice in the future.

    Tune in to this podcast to learn about the latest advances in KRAS G12C inhibitors, antibody-drug conjugates and anti-TIGIT antibodies, as well as the most promising neoadjuvant therapeutic strategies being studied. The panel also consider the use of biomarkers for evaluating response to immunotherapy and the importance of lung cancer screening programs.

    The post The Lung Cancer Sessions: highlights from IASLC WCLC appeared first on VJOncology.

    The GI Cancer Sessions: Highlights from ASCO GI 2021 Feb 12, 2021

    The virtual American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium 2021 brought together leading experts in GI cancer who updated the community on the latest data and hot topics in the field.

    In this podcast, Tobias Arkenau, MD, PhD, Sarah Cannon Research Institute UK, London, UK, chairs an insightful panel discussion on the some of exciting developments presented at ASCO GI 2021 in colorectal, gastric and bile duct cancer. He was joined by Lizzy Smyth, MD, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK, Nataliya Uboha, MD, PhD, University of Wisconsin, Madison, WI and Kai-Keen Shiu, FRCP, PhD, University College London Hospitals NHS Foundation Trust, London, UK.

    Hear the expert panel offer their perspectives on pembrolizumab in colorectal cancer & KEYNOTE-177, the latest studies evaluating therapies targeting FGFR2 and HER2 in both gastric cancer and cholangiocarcinoma, CAR-T advances in GI cancer and how the gut microbiome could be used to predict response to immune-checkpoint blockade.

    The post The GI Cancer Sessions: Highlights from ASCO GI 2021 appeared first on VJOncology.

    The Breast Cancer Sessions: Highlights from SABCS 2020 Jan 25, 2021

    The virtual San Antonio Breast Cancer Symposium (SABCS) 2020 brought together leading experts in breast cancer who updated the community on the latest data and hot topics in the field.

    In this podcast, Erika Hamilton, MD, Sarah Cannon Research Institute, Nashville, TN, speaks to Matteo Lambertini, MD, PhD, University of Genova, IRCCS Ospedale Policlinico San Martino, Genova, Italy and Sibylle Loibl, MD, PhD, German Breast Group, Neu-Isenburg, Germany to discuss the latest advances.

    The expert panel offer their highlights from SABCS 2020, including the latest trials evaluating CDK4/6 inhibitors in early breast cancer, weighing up the reported data from PENELOPE-B, monarchE and PALLAS and what this means for HR+/HER2- early-stage breast cancer. They also discuss the RxPONDER data and the subgroup analysis based on menopausal status and what it may tell us about adjuvant chemotherapy in these patient populations. The panel also consider the range of immunotherapies being studied in breast cancer and how they plan to determine which chemotherapy backbone to combine with each immune checkpoint inhibitor. Other highlights include the safety of pregnancy after breast cancer and the importance of randomized phase III trials.

    The post The Breast Cancer Sessions: Highlights from SABCS 2020 appeared first on VJOncology.

    SABCS 2020 highlights: immunotherapy, novel agents & trial updates Jan 08, 2021

    In December, the San Antonio Breast Cancer Symposium (SABCS) 2020 convened virtually and featured key updates in the treatment and management of breast cancer, including the latest data in immune-oncology, novel targeted therapies, and many highly anticipated trial updates.

    In this podcast, Sangeetha Reddy, MD, of UT Southwestern Medical Center, Dallas, TX, Bora Lim, of The University of Texas MD Anderson Cancer Center, Houston, TX, and Matteo Lambertini, MD, PhD of IRCCS AOU San Martino (Ospedale Policlinico San Martino), Genova, Italy, discuss treatment approaches in breast cancer, including the latest trial data, as well as immunotherapy and targeted agents currently being explored in this patient population.

    The Breast Cancer Podcasts on VJOncology are supported by Seagen. Seagen have no influence over the production of the content.

    The post SABCS 2020 highlights: immunotherapy, novel agents & trial updates appeared first on VJOncology.

    Key trial updates at SABCS 2020: monarchE, RxPONDER & ASCENT Dec 15, 2020

    The San Antonio Breast Cancer Symposium (SABCS) 2020 annual meeting took place virtually this year and showcased recent advances in the treatment and management of breast cancer.

    In this podcast, Priya Rastogi, MD, of the University of Pittsburgh, Pittsburgh, PA, Sara M. Tolaney, MD, MPH, of the Dana-Farber Cancer Institute, Boston, MA, and Sara Hurvitz, MD, of Ronald Reagan UCLA Medical Center, Los Angeles, CA, outline key trial updates presented at SABCS 2020, including the primary outcome results of the monarchE study (NCT02107703), the practice-changing findings of RxPONDER (NCT01272037), and the updated biomarker analysis of the ASCENT study (NCT02574455). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

    The post Key trial updates at SABCS 2020: monarchE, RxPONDER & ASCENT appeared first on VJOncology.

    Updates in non-small cell lung cancer from ESMO Nov 03, 2020

    Significant advances have been made in the treatment of non-small cell lung cancer (NSCLC), the most common form of lung cancer. The latest trial updates in oncogene-targeted therapy for patients with advanced ALK-positive NSCLC were presented during the European Society for Medical Oncology (ESMO) 2020 Virtual Congress.

    In a planned interim analysis of the Phase III CROWN trial, lorlatinib significantly improved progression-free survival compared with crizotinib. Additionally, insights from sub-analyses of the Phase III ALTA 1L study support the evidence of intracranial efficacy with brigatinib for patients with ALK-positive NSCLC as well as associated quality of life data.

    In this podcast, Sanjay Popat, BSc, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, details recent results of both the CROWN and ALTA-1L trials and sheds light on new potential NSCLC front-line treatments.

    This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

    The post Updates in non-small cell lung cancer from ESMO appeared first on VJOncology.

    Highlights from EADO 2020: novel therapies, neoadjuvant approaches & COVID-19 Oct 29, 2020

    The 16th European Association of Dermato-Oncology (EADO) meeting took place virtually this year and provided an opportunity to hear from worldwide recognized experts in the field of skin cancers and melanoma, as well as the impact of the COVID-19 pandemic on cancer care.

    In this podcast, Michael Postow, MD, of Memorial Sloan Kettering Cancer Center, New York, NY, Alexander van Akkooi, MD, PhD, of Netherlands Cancer Institute, Amsterdam, The Netherlands, and Bettina Ryll, MD, PhD, of the Melanoma Patient Network Europe, Uppsala, Sweden, discuss novel therapies in melanoma, neoadjuvant approaches and the impact of COVID-19 on the treatment and management of skin cancers in Europe. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

    The post Highlights from EADO 2020: novel therapies, neoadjuvant approaches & COVID-19 appeared first on VJOncology.

    The Lung Cancer Sessions: learnings from the ESMO 2020 Science Weekend Oct 14, 2020

    The European Society for Medical Oncology (ESMO) 2020 Virtual Congress brought together leading experts in oncology who updated the community on the latest data and hot topics in many disease areas, including lung cancer.

    In this podcast, Solange Peters, MD, PhD, University Hospital Vaudois, Lausanne, Switzerland, Martin Reck, MD, PhD, German Center of Lung Research, Grosshansdorf, Germany and Sanjay Popat, BSc, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, UK, discuss the latest advances in oncogene-targeted therapy in the first-line treatment of patients with advanced ALK-positive non-small cell lung cancer (NSCLC), reviewing data from the CROWN, ALEX and ALTA-1L studies. The panel also discusses the latest data presented from the ADAURA study in patients with resected EGFR-mutated NSCLC, as well as the outcomes from the LungART study, and the impact of the data presented for guidelines going forward in post-operative radiotherapy in NSCLC. Finally, our expert panel concludes the session by outlining to the latest immuno-oncology updates in NSCLC and small cell lung cancer (SCLC).

    The post The Lung Cancer Sessions: learnings from the ESMO 2020 Science Weekend appeared first on VJOncology.

    The ONS/EONS Congress Roundtable Discussion with VJOncology and OncoAlert Sep 10, 2020

    The treatment of cancer continues to evolve rapidly, with expanded therapeutic options and changes to clinical practice. Additionally, the care of patients with cancer has been complicated in 2020 by the COVID-19 pandemic. Oncology nurses are at the forefront of cancer care, looking after patients and their carers day-to-day. It is therefore vital to share information and educate nurses to maintain their knowledge and skills, to ensure the best care for their patients.

    In this podcast, Gilberto Morgan, MD, Skåne University Hospital, Lund, Sweden, chairs a thoughtful discussion with Darcy Burbage, DNP, RN, AOCN, CBCN, Oncology Clinical Nurse Specialist, Director-at-Large, Oncology Nursing Society, Christine Ladd, MSN, RN, OCN, Patient Care Services, Sentara Norfolk General & Sentara Independence Infusion Centers, VA, and Helena Ullgren, ONS, MSc Palliative care, PhD Student, Karolinska University Hospital and Regional Cancer Center, Stockholm-Gotland, Sweden, on the most important updates and the latest research in oncology nursing and how it all affects Medical Oncologists. The topics covered include innovative approaches to improve patient care, precision medicine, COVID-19 and cancer care, and supporting informal caregivers.

    The post The ONS/EONS Congress Roundtable Discussion with VJOncology and OncoAlert appeared first on VJOncology.

    Prioritizing patients for breast cancer surgery during COVID-19 Aug 03, 2020

    Patients with cancer consistently demonstrate poorer post-COVID-19 infection outcomes, and as a result of the pandemic, cancer services within the UK have shifted to protect patient survival. In the breast cancer field, the surgical management of primary breast cancer has also been affected, with many ER+ HER2- patients being deferred from surgery to neoadjuvant endocrine therapy due to safety concerns and resource availability. Therefore, the identification of primary breast cancer patients at greater need for surgical intervention is of great importance.

    In this podcast, Peter Barry MBBS (Hons), MPhil, FRACS, Royal Marsden NHS Foundation Trust, London, UK, discusses a recent publication in npj Breast Cancer evaluating an evidence-based treatment algorithm designed to identify patients with post-menopausal primary ER+ HER2- breast cancer who should be prioritized for surgery or, based on ER and progesterone receptor status at diagnosis, be appropriate for neoadjuvant endocrine therapy.

    This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

    The post Prioritizing patients for breast cancer surgery during COVID-19 appeared first on VJOncology.

    Genotyping in lung cancer and multi-cancer detection Jul 01, 2020

    Using precision genotyping for identifying resistance mechanisms in advanced lung cancer can help guide treatment decisions and prolong the benefit of targeted therapy. Advancements in the use of circulating tumor cell-free DNA (cfDNA) has simplified this procedure to look for multiple mutations, although further tests are usually needed to confirm the mutation present.

    The use of cfDNA has also been evaluated for the detection of multiple cancer types, and a recent publication in the Annals of Oncology showed that over 50 cancer subtypes can be successfully detected, paving the way for earlier detection, earlier treatment and potentially higher survival rates.

    In this podcast, Geoffrey Oxnard, MD, Dana-Farber Cancer Institute, Boston, MA, firstly discusses the use of liquid biopsy in genotyping for resistance mechanisms in lung cancer, the importance of genotyping patients upfront and some practical comments on sequencing of biopsies and treatment. Dr Oxnard also discusses the data from the multi-detection of cancers study.

    This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

    The post Genotyping in lung cancer and multi-cancer detection appeared first on VJOncology.

    Molecular testing for lung cancer in the UK May 13, 2020

    Molecular testing for lung cancer mutations plays an important role in the care of patients, by enabling quicker access to the most appropriate treatments. The guidelines from the National Institute for Health and Care Excellent (NICE) are clear on what molecular testing is required for patients in the England. However, although testing rates are high, further work is ongoing to improve this process.

    In this podcast, Neal Navani, MA, MRCP, MSc, PhD, Care Quality Improvement Department, Royal College of Physicians, London, UK firstly discusses molecular testing in the UK, highlighting real-world evidence from the National Lung Cancer Audit. Next, Sanjay Popat, BSc, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, UK, highlights the importance of molecular testing and the formation of the Genomic Laboratory Hubs (GLHs) in England, which will help to coordinate the national approach to providing molecular diagnostic tests for patients. Finally, Angela George, MB, ChB, FRACP, MD, the Royal Marsden NHS Foundation Trust, London, UK, then reviews a paper she co-authored investigating next-generation sequencing (NGS) and single-gene testing for lung cancer testing, and how comprehensive genomic profiling aids patient care.

    These interviews took place at the 18th British Thoracic Oncology Group (BTOG) 2020 congress held in Dublin, UK.

    The post Molecular testing for lung cancer in the UK appeared first on VJOncology.

    Living with and beyond cancer: a patient’s quality of life is just as important as survival Feb 04, 2019

    The views of patients with cancer, and their survivorship, is becoming increasingly important to cancer research. This podcast not only highlights the importance of patient involvement in setting the research agenda, but also reveals the challenges, next-steps, and progress being made in the development of treatments and knowledge regarding all aspects of cancer. In this podcast, our featured experts give us an overview of the challenges surrounding cancer survivorship and how they can be addressed going forward.

    This podcast features: Galina Velikova, PhD, of the University of Leeds, Leeds, UK; Andrew Bottomley, PhD, of the European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium; Adrian Edwards, MBBS, MPhil, PhD, from the University of Cardiff, Cardiff, UK; Diana Greenfield, RN, PhD, of Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK; Gemma Pearce, PhD, from Coventry University, Coventry, UK; and Bernard Rachet, MD, PhD, FFPH, of the London School of Hygiene and Tropical Medicine, London, UK. These conversations took place at the 2018 National Cancer Research Institute (NCRI) Cancer Conference, held in Glasgow, UK.

    The post Living with and beyond cancer: a patient’s quality of life is just as important as survival appeared first on VJOncology.

    Advancing immunotherapy for solid tumors Nov 23, 2018

    Immunotherapy has the potential to treat all types of cancer, making it a highly lucrative area of research. Since the first FDA-approved immunotherapy for bladder cancer in 1990, the Bacillus Calmette-Guérin cancer vaccine, many more agents have arrived on the scene. A challenge in this field is not only finding the right therapeutic targets and optimizing efficacy, but also managing the immune-related side effects. In this podcast, our experts explore the use of immunotherapies in solid tumors.

    James Spicer, FCRP, PhD, MRCP, MBBS, from Guy’s and St Thomas’ NHS Foundation Trust, London, UK, Michael Pishvaian, MD, PhD, from Georgetown University, Washington, WA, Marina Garassino, MD, from the National Cancer Institute of Milan, Milan, Italy, Barbara Burtness, MD, from Yale School of Medicine, New Haven, CT, Thomas Gajewski, MD, PhD, from the University of Chicago Comprehensive Cancer Center, Chicago, IL, Michel Sadelain, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, and Hans Hammer, MD, PhD, from the University of Texas Southwestern Medical Center, TX, USA, discuss a range of topics, including recent advancements, molecular targets, the current and future landscapes of immunotherapy, including CAR T-cells, as well as some of the challenges associated with patient selection and the immunotherapeutic treatment of solid tumors. All interviews were recorded at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.

    The post Advancing immunotherapy for solid tumors appeared first on VJOncology.

    Updates in breast cancer: recent clinical trials, immunotherapy, challenges & future treatment outlook Oct 11, 2018

    This is an exciting time in the breast cancer field, with advances in the development of treatments and knowledge regarding all aspects of breast cancer. In this podcast, Robert Coleman, MBBS, MD, FRCP, FRCPE, of the University of Sheffield, Sheffield, UK, Howard Burris, MD, FACP, FASCO, of Sarah Cannon Research Institute, Nashville, TN, Peter Fasching, MD, of University Hospital Erlangen, Erlangen, Germany, and Aditya Bardia, MD, MPH, of Massachusetts General Hospital, Boston, MA, discuss exciting updates in clinical trials, immunotherapy and future treatments for breast cancer at the American Society of Oncology (ASCO) Annual Meeting 2018. We also have Nazneen Rahman, CBE, FMedSci, of the Institute of Cancer Research, London, UK, giving us an overview of the challenges surrounding genetic testing for breast cancer from the 2017 National Cancer Research Institute (NCRI) Conference, held in Liverpool, UK.

    The post Updates in breast cancer: recent clinical trials, immunotherapy, challenges & future treatment outlook appeared first on VJOncology.

    Hot topics in oncology: precision medicine, biomarkers & immunotherapy Sep 14, 2018

    In preparation for the ESMO 2018 congress, we’ve put together a series of hot topics in oncology summing up themes from the most recent oncology conferences. In this podcast, Neal Navani from University College London Hospitals NHS Foundation Trust, Wolfgang Wick of the German Cancer Research Center, Howard Burris of the Sarah Cannon Research Institute, James Spicer of Guy’s and St Thomas’ NHS Foundation Trust, and Thomas Powles from Barts Cancer Institute, discuss cancer screening, personalized medicine, biomarkers and immunotherapy, including CAR T-cells.

    This podcast provides an overview of some of the most important themes in oncology right now. The interviews included were recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, the British Thoracic Oncology Group (BTOG) Annual Conference 2018, and the 2018 Genitourinary Cancers Symposium.

    The post Hot topics in oncology: precision medicine, biomarkers & immunotherapy appeared first on VJOncology.

    Bladder cancer: advances in the spotlight and what these mean for therapy Aug 16, 2018

    Over the past few years, the field of bladder cancer has seen an array of exciting clinical advancements, ranging from novel therapies, to prognostic biomarkers and disease biology. Exploring these developments and their implications, this podcast features Thomas Powles of Barts Cancer Institute, Andrea Apolo of the National Cancer Institute, Rob Jones of the University of Glasgow & Beatson West of Scotland Cancer Centre, and Arlene Siefker-Radtke of the MD Anderson Cancer Center.

    Footage of the speakers was recorded at the 2018 Genitourinary (GU) Cancers Symposium and the American Society of Oncology (ASCO) 2018 Annual Meeting.

    The post Bladder cancer: advances in the spotlight and what these mean for therapy appeared first on VJOncology.

      Related Podcasts

      The Eat for Endurance Podcast

      1

      The Eat for Endurance Podcast Health & Fitness
      BFF: Black, Fat, Femme

      2

      BFF: Black, Fat, Femme Health & Fitness
      Circle Up!

      3

      Circle Up! Fitness
      Emergency Services – Coláiste Stiofáin Naofa

      4

      Emergency Services – Coláiste Stiofáin Naofa Government & Organizations
      Stay Off My Operating Table

      5

      Stay Off My Operating Table Health & Fitness
      Elite Man Podcast

      6

      Elite Man Podcast Alternative Health
      footer-logo

      Contact Us

      Toll Free: 844-670-7747

      Links

      • Home
      • Top Charts
      • Networks
      • Apps
      • Independents Podcasts
      • Podcast Advertising
      • Podcast News
      • Contact Us
      • About Us
      • Analytics & Insights

      Stay Connected

        Privacy, Terms of Use & Our Code of Ethics Protecting Content Creators Copyrights